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ABSTRACT 
 
The tumor suppressor p53 plays a central role in the protection against DNA damage 
and other forms of stress, primarily by inducing cell cycle arrest or apoptosis. 
Missense mutation of p53, which is one of the most frequent genetic alterations 
detected in human cancers, inactivates these growth regulatory functions; in addition, 
mutant p53 often acquires tumor-promoting activities (gain-of-function). A complete 
and thorough understanding of the signaling circuitry that regulates wild-type and 
mutantp53 functions is therefore a primary objective for basic cancer research, since it 
may lead to development of important tools for diagnosis and therapy of tumors. One 
crucial component of such knowledge is the molecular mechanism leading to protein 
activation. 
Deregulated ribosome biogenesis is commonly observed in cancers as a result of 
increased biosynthetic demand due to uncontrolled cell proliferation. Cells actively 
monitor the fidelity of ribosome biogenesis, activating cellular checkpoints when this 
process is altered. Indeed, perturbations to many aspects of ribosome biogenesis 
generate a “nucleolar stress” that triggers a p53 response. Evidence in animal models 
indicates that the ribosomal-p53 checkpoint is indeed important for tumor suppression 
in vivo. 
In the recent past, we identified the nucleolar protein GTPBP4 as a novel p53 
interactor, and established a functional link between the two proteins by 
demonstrating that GTPBP4 depletion promotes p53 accumulation and activation. 
In this Thesis, I demonstrate that GTPBP4 depletion affects 28S rRNA processing, 
generating a “nucleolar stress” responsible for p53 stabilization. The molecular 
mechanism responsible for such accumulation relies on the binding of ribosomal 
proteins to Mdm2. In parallel, I report that the same molecular mechanism leading to 
wild-type p53 stabilization upon ribosomal stress, can also promote mutant p53 
accumulation in cancer cells. Thus, deregulated ribosome biogenesis may contribute 
to the stability of mutant p53 in tumors. 
These results collectively suggest that upon alterations in ribosome biogenesis, the 
TP53 status may be critical to drive the nucleolar surveillance pathway towards a 
tumor suppressive or oncogenic outcome.   
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FOREWORD 
 
During my PhD I worked on two different projects. Although both concern the 
analysis of the effects of deregulated ribosome biogenesis in cancer progression, they 
are markedly distinct; for this reason I describe them as separate parts in this Thesis. 
 
The first project is focused on the molecular mechanism leading to p53 accumulation 
upon depletion of the nucleolar protein GTPBP4. This project derived from a study 
that was made in our laboratory and that was already published (Lunardi et al., 2010). 
This work is described in PART 1. 
 
The second project stemmed from some observations made during the previous 
project, and is focused on the study of a molecular link between deregulated ribosome 
biogenesis and mutant p53. This work is described in PART 2. 
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PAPERS NOT DIRECTLY RELEVANT TO THE THESIS 
 
During my PhD I was also involved in a collaboration to study the impact of some 
Parkinson‟s disease associated proteins on ribosome biogenesis and rRNA 
maturation. This collaboration led to the following publications: 
 
Parkinson's disease DJ-1 L166P alters rRNA biogenesis by exclusion of TTRAP from 
the nucleolus and sequestration into cytoplasmic aggregates via TRAF6. 
Vilotti S, Codrich M, Dal Ferro M, Pinto M, Ferrer I, Collavin L, Gustincich S, 
Zucchelli S. PLoS One. 2012. 
 
The PML nuclear bodies-associated protein TTRAP regulates ribosome biogenesis in 
nucleolar cavities upon proteasome inhibition. 
Vilotti S, Biagioli M, Foti R, Dal Ferro M, Lavina ZS, Collavin L, Del Sal G, 
Zucchelli S, Gustincich S. Cell Death Differ. 2012. 
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INTRODUCTION 
  
Cancer is a complex disease involving dynamic changes in the genome that allow 
cells to bypass those regulatory circuits which modulate normal cell proliferation and 
homeostasis. Besides many individual differences, all human tumors share common 
features: self-sustained proliferative abilities, insensitivity to growth inhibitors and 
apoptosis, limitless replicative potential, sustained angiogenesis, and acquired ability 
to invade and metastasize (Hanahan and Weinberg, 2000). Besides these six features, 
human tumors may take advantage from an inflammatory microenvironment 
(Mantovani, 2009), and from reprogramming cellular metabolism to sustain 
deregulated cell proliferation (Hanahan and Weinberg, 2011). 
From a molecular point of view, oncogenic transformation is a multistep process 
characterized by a gradual alteration of normal cells into cancerous cells and requires 
alterations in various cellular processes including both activation of oncogenic 
pathways and inhibition of tumor suppressor pathways, therefore promoting growth 
and survival of cancer cells  (Hanahan and Weinberg, 2000). 
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The p53 pathway 
 
Among the tumor suppressor pathways frequently deregulated in cancer, that of p53 is 
one of the most important. The hub of this pathway is the protein p53, a transcription 
factor that was discovered in 1979, as a protein associated with simian virus 40 
(SV40) large T-antigen (Kress et al., 1979; Lane and Crawford, 1979; Linzer and 
Levine, 1979). More than 30 years of research unveiled the complexity and the 
importance of the p53 pathway in tumor suppression. p53 is indeed at the center of a 
signaling network: many upstream pathways that work as a sensor for a great variety 
of potentially oncogenic stresses, converge to p53, which in turn translates stress 
signals into different cellular outcomes (Kruse and Gu, 2009). For this crucial role, 
p53 has been defined the “guardian of the genome” (Lane, 1992). 
 
 
FIGURE 1. Simplified scheme of the p53 pathway. The p53–MDM2 feedback loop is the „heart‟ of 
the p53 pathway. Under normal conditions, it maintains constantly low steady-state p53 levels and 
activity. Various stress signals, related in many ways to carcinogenesis, impinge on this central loop to 
release p53 from MDM2-mediated inhibition. This increases p53 protein levels and activity, inducing 
various phenotypic changes. The downstream effects of p53 are largely due to its ability to 
transactivate and repress various subsets of target genes; however, at least in the case of apoptosis, 
protein–protein interactions also have an important role. The nature of the phenotypic response to p53 
activation is, at least partially, proportionate to the amplitude, duration and nature of the activating 
signal. Severe stress induces more extreme, usually irreversible, responses, namely apoptosis and 
senescence, whereas milder stress leads to a transient growth arrest coupled with an attempt to deal 
with the cause of stress and repair the damage caused by it. Recent evidence indicates that p53 also has 
an important role in enabling the cell to adjust its metabolism in response to mild normal physiological 
fluctuations, including those in glucose and other nutrient levels, oxygen availability and reactive 
oxygen species levels. (Levine and Oren, 2009). 
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The core of this complex pathway is the regulatory mechanism that controls p53 
protein levels. Under physiological conditions p53 is maintained at low levels by 
continuous ubiquitination by its major E3 ubiquitin ligase Mdm2 and subsequent 
degradation by 26S proteasome (Haupt et al., 1997; Kubbutat et al., 1997).  Many 
stress signals can impinge on this regulatory axis, leading to p53 stabilization, 
accumulation and activation. These events are regulated by a defined combination of 
post-translational modifications within p53 and by  protein-protein interactions. Once 
activated, p53 acts mainly as a transcription factor able to promote the expression of a 
set of genes whose expression mediates different cellular outcomes such as cell cycle 
arrest, senescence or apoptosis (Junttila and Evan, 2009). 
The importance of the p53 pathway in tumor suppression is highlighted by the fact 
that the p53 gene is mutated in more that 50% of human cancers (Brosh and Rotter, 
2009), while in the remaining cancers, mutations affecting upstream or downstream 
components of the p53 regulatory network are frequently found, thus perturbing the 
outcome of p53 pathway functionality (Vousden and Lane, 2007; Vousden and 
Prives, 2009). Moreover, patients affected by the Li-Fraumeni syndrome, in which 
one mutant allele of p53 is germ-line inherited, show increased chance of developing 
early-onset cancers (Malkin et al., 1990). Finally, mice homozygous for the null allele 
of p53 have normal embryonic development but are prone to the spontaneous 
development of a variety of neoplasms by 6 months of age (Donehower et al., 1992). 
 
The p53 protein 
p53 is a 393 aa protein with evolutionary conserved functional domains: an N-
terminal transactivation domain (TAD), a prolin-rich domain (PR), a central DNA-
binding domain (DBD), an oligomerization domain (OD) and a C-terminal regulatory 
domain.  
The N-terminal TAD is crucial for p53 transcriptional activity since it mediates the 
interaction with components of the basal transcriptional machinery. Moreover is 
finely regulated both by post-translational modifications and by interaction with p53 
partners such as p300/CBP, Mdm2 and Pin1 (Mantovani et al., 2004; Mantovani et 
al., 2007; Marine and Lozano, 2010).  
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FIGURE 2. Schematic representation of human p53. (A) Structure of the human p53 gene: 
alternative splicing (α, β, γ) and alternative promoters (P1, P1‟ and P2) are indicated. (B) p53 protein 
isoforms: p53, p53β and p53γ proteins encoded from P1 or P1‟ promoters contain the conserved N-
terminal domain of transactivation (TA). Δ133p53 isoforms encoded from promoter P2 are amino-
truncated proteins deleted of the entire TA domain and deleted of part of the DNA-binding domain. 
Translation is initiated at ATG-133. Δ40p53 protein isoforms encoded from P1 or P1‟ promoters are 
amino-truncated proteins due to alternative splicing of exon 2 and/or alternative initiation of translation 
at ATG-40). Δ40p53 protein isoform have lost the conserved N-terminal domain of transactivation, but 
still contain part of the transactivation domain. Δp53 protein isoform is due to noncanonical alternative 
splicing between the exon 7 and 9. Δp53 has lost 66 residues including the highly conserved domain V 
of the DNA-binding domain. The isoforms Δp53β, Δp53γ, Δ40Δp53, Δ40Δp53β, Δ40Δp53γ, 
Δ133Δp53, Δ133Δp53β and Δ133Δp53γ should theoretically be generated (Bourdon, 2007). 
 
The PR domain (aa 61-94) derives its name from the presence of five repeats of the 
amino acid motif PXXP (P=prolin; X=any amino acid). The PXXP motifs may 
influence both p53 function, by indirectly affecting p53 acetylation by p300 (Dornan 
et al., 2003) and stability, since the prolyl isomerase Pin1, upon Thr81 
phosphorylation, binds to Thr81-Pro82 site and induces a conformational change 
leading to reduced Mdm2 binding and increasing p53 stability (Zacchi et al., 2002). 
The central region of the protein contains the sequence-specific DNA binding domain 
that is essential for the p53 activity as a transcriptional factor. The canonical p53–
responsive element (RE) contains two copies of the 10 base pair motif 5'-
PuPuPuC(A/T)(T/A)GPyPyPy-3' separated by 0-13 base pairs  (el-Deiry et al., 1992). 
Besides DNA, the DBD is bound also by p53 cofactors that play important roles in 
defining p53 functions, such as Hzf and ASPP proteins (Ahn et al., 2009; Das et al., 
2007) that positively affect p53 activities and other proteins that negatively regulate 
p53, such as Mdm2. Mdm2 indeed has been shown to interact also with DBD 
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(Shimizu et al., 2002) and this interaction strengthens the binding between the two 
proteins (Dawson et al., 2003). 
The oligomerization domain (OD) is required for the formation of a high affinity 
DNA binding and transcriptional competent p53 tetramer (Shieh et al., 1999). 
The C-terminal (CT, aa 364-393) domain of p53, in particular the last 30 amino acid 
is a regulatory domain for p53 activity, indeed, upon stress signaling, it undergoes a 
great number of post translational modifications at almost every residue that are 
essential for p53 activity (Kruse and Gu, 2009). 
Interestingly, additional p53 isoforms have been identified, but their biological 
functions and expression are still largely unknown. An alternative internal promoter 
coupled to alternative initiation and splicing sites allow for nine distinct isoforms. The 
alternative splicing of the intron 9 produces three isoforms different in their C-
terminus: p53 (or p53α), p53β and p53γ, with p53β and p53γ lacking the 
oligomerization domain. The use of an alternative initiation of translation or an 
alternative splicing of intron 2 may encode for Δ40p53, which lacks part of the TAD, 
while, an alternative promoter in intron 4 (P2) leads to the expression of an amino-
terminally truncated p53 protein (Δ133p53) (Machado-Silva et al., 2010). 
 
Mechanism involved in the regulation of p53 
Modulation of p53 stability 
In normal physiological conditions, p53 levels are kept low by ubiquitin-dependent 
proteasomal degradation (Vogelstein et al., 2000). Upon stress conditions post-
translational modifications and interaction with different partners promote p53 
stabilization and activation, thereby leading to a fully active protein (Kruse and Gu, 
2009).  
p53 inhibition occurs mainly through the E3 ubiquitin ligase Mdm2. Mdm2 regulates 
p53 in two ways by direct binding at the N-terminal of the protein, masking the TAD 
to the basal transcriptional machinery, and by promoting p53 C-terminal lysine 
ubiquitination (Clegg et al., 2008). Mdm2 promotes both mono- and poly-
ubiquitination of p53; when p53 is mono-ubiquitinated, it is exported into the 
cytoplasm and translocates at the mitochondria (Marchenko et al., 2007). Conversely, 
p53 poly-ubiquitination induces its degradation by the 26S proteasome (Lee and Gu, 
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2010). p53, in turn, promotes the expression of Mdm2, thus generating a negative 
feedback loop controlling its own levels (Stommel and Wahl, 2005). The other 
important regulator of the Mdm2-p53 axis is MdmX (Shvarts et al., 1996). Mdm2 and 
MdmX are structurally related proteins, however, despite its sequence homology with 
Mdm2 and the presence of a RING domain, MdmX does not have intrinsic E3-ligase 
activity for p53. By binding Mdm2, MdmX can instead promote its activity towards 
p53 (Linares et al., 2003) and inhibits p53-induced transcription by masking its 
transactivation domain (Oliner et al., 1993). Mdm2 and Mdmx are thus non redundant 
p53 inhibitors, and this is further highlighted by the fact that both are overexpressed 
in several cancers acting as oncogenes (Bond et al., 2004; Danovi et al., 2004).  
Many proteins can modulate Mdm2-p53 interaction. Upon oncogenic signaling, the 
tumor suppressor ARF (p14 alternative reading frame) increases p53 stability down-
modulating Mdm2 ubiquitin ligase activity by sequestering it to the nucleolus (Brooks 
and Gu, 2004). Notably, p53 itself down-regulates ARF expression (Robertson and 
Jones, 1998). Similarly, p53 stabilization and activation is affected by other pathways 
that crosstalk with the Mdm2-p53 axis. For example the AKT kinase phosphorylates 
Mdm2 inducing its translocation into the nucleus, where it down-regulates p53. 
Conversely, the tumor suppressor PTEN inhibits AKT, thus promoting p53 levels 
(Mayo and Donner, 2002). The positive feed-back loop is realized by p53, that 
promotes PTEN expression at a transcriptional level (Stambolic et al., 2001).  
Upon stress, p53 activity rapidly increases, and the required step is the abrogation of 
Mdm2-mediated degradation. This is achieved by the action of different kinases, such 
as ATM, Chk1 and Chk2, that upon stress signaling lead to the coordinated 
phosphorylation of p53, Mdm2 and MdmX, thus releasing p53 from negative 
regulation (Efeyan and Serrano, 2007). Mdm2 and MdmX phosphorylation, enhance 
their degradation by both auto-ubiquitination and by reduced association with the de-
ubiquitinating enzyme HAUSP, which in turn, can promote also p53 de-ubiquitination 
(Brooks et al., 2007). 
Furthermore, the cytoplasmic ubiquitin protease USP10 plays an important role in 
modulating p53 localization and stability. Indeed, USP10 specifically de-ubiquitinates 
p53, thereby reversing Mdm2-induced p53 nuclear export and degradation (Yuan et 
al., 2010). 
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In addition to Mdm2, a number of other p53 E3-ubiquitin ligases have been described 
in the last decade. Among them Pirh2 and COP1, are p53-induced genes that 
participate in an auto regulatory negative feedback loop similar to that of Mdm2 
(Dornan et al., 2004; Leng et al., 2003). 
 
p53 post-translational modifications 
p53 is subjected to a great variety of post-translational modifications (PTMs) that 
influence its stability and transcriptional activity. Most of these modifications occur 
both at the N- and C-terminal of the protein. In general, the N-terminal 
phosphorylations affect p53 stability and allow the C-terminal acetylations that, in 
turn,  promote p53 transcriptional activity. More than 36 residues within p53 have 
been reported to be modified. Besides phosphorylation and acetylation, p53 is mono- 
and poly-ubiquitinated, sumoylated, neddylated, and methylated (Kruse and Gu, 
2009). 
 
 
 
Figure 3. Overview of p53 domain structure and post-translational modifications. The major sites 
for p53 phosphorylation, ubiquitination, neddylation, sumoylation, acetylation and methylation are 
plotted. The enzymes responsible for each type of modification are shown on the right. Abbreviations: 
TAD, transactivation domain; PRD, proline rich domain; DBD, DNA-binding domain; TD, 
tetramerization domain; CRD, C-terminal regulatory domain (Dai and Gu, 2010). 
 
Phosphorylation. Phosphorylation is the best characterized p53 post-translational 
modification. Many kinases, including ATM, ATR, Chk1, Chk2, CK1, CK2, JNK, 
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Erk, HIPK2, and others, have been reported to phosphorylate p53 after cellular stress 
(Kruse and Gu, 2009; Vousden and Prives, 2009). Interestingly, a single site can be 
phosphorylated by different kinases and vice versa a single kinase can phosphorylate 
different sites. This redundancy might be explained as a failsafe mechanism of 
protection or by the fact that a distinctive pattern of phosphorylation is required for 
further modifications, thus allowing a fully and specific activation (Kruse and Gu, 
2009). There are, however, residues that are constitutively phosphorylated in 
unstressed conditions and are dephosphorylated following stress (e.g. T55) (Li et al., 
2007).  
Acetylation. Acetylation is a powerful mechanism to promote p53 stability and 
transcriptional activity. Indeed C-terminal lysines acetylation excludes ubiquitination 
on the same sites and prevents the formation of Mdm2/MdmX inhibitory complexes 
on target gene promoters; moreover, it allows recruitment of cofactors essential for 
p53 transcriptional activity (Dai and Gu, 2010) .   
Histone Acetyl transferases (HATs), such as  p300/CBP and PCAF (p300/CBP-
associated factor), are responsible for p53 acetylation in response to DNA damaging 
agents, such as UV- and γ-irradiation (Carter and Vousden, 2009). Conversely, the 
equilibrium in p53 acetylation is maintained by Histone Deacetylases (HDACs), such 
as HDAC1 and SIRT1 (Luo et al., 2001; Luo et al., 2000).  
 
Regulation by co-factors 
There are proteins that affect p53 activity by selective interaction with the tumor 
suppressor, indeed, more than 150 p53-interacting proteins have been described so far 
(source: BioGrid and Mint databases). Many of them, influence specifically p53 
transcriptional activity, and thereby its functions, acting as co-activators or co-
repressors. For example, ASPP (Apoptosis stimulating proteins of p53) family 
members ASPP1 and ASPP2 enhance the proapoptotic function by selectively 
promoting the binding of p53 to proapoptotic genes like BAX, PUMA and PIG3 
(Samuels-Lev et al., 2001), conversely, iASPP (inhibitory member of the ASPP 
family) prevents transcriptional activity of p53 bound to pro-apoptotic promoters 
(Bergamaschi et al., 2003).  
Some p53 interactors possess histone modifying activity, suggesting that targeted 
chromatin remodeling might be important for p53 transcriptional activity. Indeed, 
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p53-dependent changes in histone acetylation have been observed at the promoter of 
many p53 target genes (Kaeser and Iggo, 2002; Shan et al., 2003).  
p53 post-translational modifications may selectively guide co-regulator recruitment, 
thus providing a means for a fine tune p53 modulation in response to different 
stresses. 
 
p53 biological functions 
Upstream events activating the p53 pathway  
A wide range of stress signals, that could affect genome integrity and cell 
proliferation, promote the activation of the p53 pathway.  
Historically, DNA damage was the first type of stress found to activate the p53 
pathway (Lane, 1992).  DNA damage can originate from exogenous stimuli, such as 
UV, ionizing radiations and from chemical mutagenic compounds, or from normal 
cellular processes such as metabolism and replication. For example, DNA damage can 
be induced by by-products of the oxidative metabolism such as reactive oxygen 
species (ROS), premature termination of replication fork progression (Branzei and 
Foiani, 2005, 2010), and by telomere erosion consequent to continuous replication 
(d'Adda di Fagagna et al., 2003). Remarkably, specifically in precancerous lesions 
and not in normal tissue, the DNA damage response pathway is permanently 
activated, suggesting that cellular transformation generates DNA damage, and cells 
activate a barrier to counteract cancer progression (Bartkova et al., 2005).  
DNA damage activates different signaling pathways that converge on p53 promoting 
a complex combination of p53 post-translational modifications necessary to promote 
its stabilization and its transcriptional activity (Kruse and Gu, 2009). The two DNA 
damage sensor kinases, ATR and ATM, and their downstream kinases Chk1 and 
Chk2, are indeed able to phosphorylate p53 at different sites, promoting its 
stabilization and activation (Hammond et al., 2002; Hirao et al., 2000; Pabla et al., 
2008; Perona et al., 2008). 
Other kinases that have been reported to phosphorylate and activate p53 in response 
to different stress signals are for example JNK, HIPK2 and p38 (Kruse and Gu, 2009).  
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Oncogenic signaling activates p53 not only through the induction of the DNA damage 
cascade, but also through the transcriptional activation of p14
ARF
 (de Stanchina et al., 
1998; Palmero et al., 1998). 
Other stimuli have been reported to induce and activate the p53 pathway: among them 
altered ribosome biogenesis (that will be discussed below), heat and cold shock 
(Ohnishi et al., 1998a; Ohnishi et al., 1998b), presence of denaturated proteins, 
depletion of ribonucleotide-phosphate pool in the cell (Khan et al., 2000), spindle 
damage leading to defective chromosomal segregation (Lanni and Jacks, 1998), nitric 
oxide production associated with infections and inflammation (Hofseth et al., 2003), 
and hypoxia (Liu et al., 2007). 
 
Outcomes of the activation of the p53 pathway 
The activation of the p53 pathway by stress signals promotes different cellular 
outcomes, such as the induction of reversible cell cycle arrest, apoptosis, senescence 
and others, depending on the cell type, the nature, duration and intensity of the 
stimuli, and finally on the protein partners that affect its stability and activity. 
Once activated, p53 acts mainly as a sequence-specific transcription factor to induce 
the expression of a large set of genes. Moreover, p53 has been also shown to promote 
cellular outcomes in a transcription-independent way, through direct interaction with 
other proteins.  
The activation of the p53 pathway can induce cell cycle arrest mostly promoting the 
expression of three target genes: p21, 14-3-3σ and GADD45 (Vousden and Lane, 
2007; Vousden and Lu, 2002). The expression of the cyclin-dependent kinase 
inhibitor p21, results in cell cycle arrest at G1 phase due to inhibition of 
cyclinE/CDK2, cyclinA/CDK2 and cyclinD/CDK4 (Harper et al., 1993), while 14-3-
3σ and GADD45 expression is responsible for p53-induced G2 arrest (Hermeking et 
al., 1997; Kastan et al., 1992). 14-3- 3σ prevents nuclear import of cyclin B1 and 
CDC2 (Chan et al., 1999) whereas GADD45 destabilizes CDC2/cyclinB complexes, 
and these two processes cooperate to prevent initiation of mitosis (Jin et al., 2002). 
Cell cycle arrest allows the activation of pathways that promote the correction of the 
damage. Indeed p53 has been reported to directly promote DNA repair through the 
modulation of nucleotide excision repair (NER), base excision repair (BER) and 
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double strand break (DSB) repair (Albrechtsen et al., 1999; Bertrand et al., 2004; 
Paquet et al., 2004). p53 is also involved in inhibiting homologous recombination 
(HR) in response to replication fork stalling (Janz and Wiesmuller, 2002) and it 
prevents the accumulation of DSBs at stalled-replication forks (Kumari et al., 2004). 
The elimination of damaged cells that might develop into malignant counterpart can 
be achieved through the induction of apoptosis (Clarke et al., 1993; Debbas and 
White, 1993).  p53 promotes apoptosis through the transcriptional modulation of 
genes involved in both the extrinsic and intrinsic pathway. p53 promotes the 
expression of genes coding for death receptors and associated proteins such as Fas, 
DR4 and KILLER/DR5, PERP and Pidd, thus activating the extrinsic apoptotic 
pathway (Balint and Vousden, 2001). Other p53 regulated genes such as Bax, Puma 
and Noxa are involved in the release of the cytochrome c from the mitochondria into 
the cytoplasm thus activating the intrinsic apoptotic pathway (Miyashita and Reed, 
1995; Nakano and Vousden, 2001) (Yu et al., 2001). p53 can promote apoptosis also 
in a transcription independent manner, in response to genotoxic, hypoxic, and 
oxidative stress a fraction of p53 translocates to the mitochondria (Marchenko et al., 
2000) where it interacts with Bcl-2, Bcl-xL, and Bak promoting the release of 
cytochrome c (Leu et al., 2004; Mihara et al., 2003).  
Another mechanism by which the p53 pathway counteracts neoplastic transformation 
is through the induction of senescence. Senescence is characterized by irreversible 
cell cycle arrest and morphological changes in the cell triggered by physiological 
conditions, such as telomeres shortening (replicative senescence), or by endogenous 
and exogenous stimuli such as oncogene activation, loss of tumor suppressor genes, 
oxidative stress and others (Itahana et al., 2004; Zuckerman et al., 2009). The p53 and 
p16/INK4a-RB pathways are mainly responsible for the execution of the proliferative 
arrest that characterizes senescence (Campisi, 2005). The main executor in mediating 
p53-induced senescence is its transcriptional target p21 (Serrano et al., 1997) which is 
transcribed as a result of the activation of the DNA damage response pathway 
(Saretzki, 2010). Several lines of evidence suggest that in vivo the induction of 
cellular senescence program is the main barrier that p53 opposes to cellular 
transformation (Xue et al., 2007). 
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In recent years, the p53 pathway has been demonstrated to be involved in the 
regulation of other cellular processes such as cell metabolism (Vousden and Ryan, 
2009), and cell polarity (Cicalese et al., 2009). 
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Mutant p53 
 
Mutations in the TP53 gene are very frequently found in human tumors, even 
exceeding 50% of cases depending on tumor type (COSMIC database 
http://cancer.sanger.ac.uk/cancergenome/projects/cosmic/).  
Unlike other tumor suppressor genes, whose expression is usually abrogated by 
deletions or truncating mutations, in the case of TP53, more than 70% of the 
mutations are missense, consequently leading to the expression of a full length 
protein, which differs from the wild-type counterpart in a single amino acid 
substitution. 
Mutations in the TP53 gene are not randomly dispersed along the whole sequence, but 
are generally found in exons 4-9, which encode for the DNA-binding domain of the 
protein (Fig. 4). Interestingly, about 30% of all p53 mutations fall within 6 “hotspot” 
codons (Hollstein et al., 1991; Petitjean et al., 2007). TP53 mutations can be grouped 
into two main categories accordingly to their effect on the thermodynamic stability of 
the p53 protein (Bullock and Fersht, 2001). Mutations affecting residues directly 
involved in DNA binding, such as R248Q and R273H, are referred to as “DNA-
contact” mutations. Conversely, mutations that cause local, such as R249S and 
G245S, or global, such as R175H and R282W, structural distortions are referred to as 
“conformational” mutations.  
 
 
 
FIGURE 4. The distribution of reported missense mutations along the p53 sequence. The six most 
common hotspot mutations are highlighted in yellow for DNA-contact mutations, green for locally 
distorted mutants and blue for globally denatured mutants. The domain architecture of p53 is aligned 
below. TA, transactivation domain; PR, proline-rich domain; DBD, DNA binding domain; Tet, 
tetramerization domain; Reg, carboxy-terminal regulatory domain. Data derived from the IARC TP53 
Database. 
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The frequency of point mutations suggests that mutation of p53 might provide to 
cancer cells a selective advantage with respect to simple loss of the protein. 
In fact, p53 mutations are involved in the process of tumorigenesis by three non-
mutually exclusive mechanisms (Brosh and Rotter, 2009). 
First, mutations abolish the tumor suppressive functions of p53, mainly reducing or 
abrogating the binding of p53 to its consensus DNA sequence, thereby preventing the 
transcriptional activation of p53 target genes (Kato et al., 2003). Wild type p53 loss of 
functions (LOF), besides missense mutations of the TP53 gene, can be achieved also 
by gene deletion and truncations, splicing and nonsense mutations. 
Second, most missense mutations produce a full length protein capable of inhibiting, 
to varying degrees, the function of the wild type protein encoded by the second allele. 
This dominant negative (DN) effect is achieved by the oligomerization of mutant with 
wild type p53. The result is a heterotetramer defective in sequence-specific DNA 
binding (Milner and Medcalf, 1991). Although this concept has been proved in 
various models, heterozygous p53mut/wt tumors are rarely detected, indicating this 
condition is not stable during cell transformation. 
Finally, mutant p53 acquires new functions, termed gain of function properties 
(GOF), not present in the wild type protein, that actively contribute to various aspect 
of tumor progression. 
 
Mechanism of the Gain of function of mutant p53 
There are multiple proposed mechanism that account for different p53 gain of 
function activities. These include both transcriptional and non-transcriptional 
mechanisms (fig. 5). 
Mutant p53 has been reported to interact with p53 family members p63 and p73 (Di 
Como et al., 1999; Gaiddon et al., 2001) and to inhibit transactivation of their target 
genes (Marin et al., 2000; Strano et al., 2002). The binding to p63 and p73 has been 
linked to the ability of mutant p53 to promote chemoresistance, migration, invasion 
and metastasis (Adorno et al., 2009; Muller et al., 2009; Sampath et al., 2001). 
Despite mut-p53 proteins are unable to recognize wt-p53 consensus (Kato et al., 
2003), mutant p53 has been shown to transactivate genes involved in different aspects 
of tumorigenesis (Brosh and Rotter, 2009; Girardini et al., 2011). A proposed 
mechanism is through the interaction with other sequence specific transcription  
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Figure 5. Selected oncogenic properties of mutant p53 and their underlying mechanisms. The 
inner circle (shaded blue) represents oncogenic phenotypes associated with the activities of mutant p53 
proteins. The outer circle depicts key mechanistic properties of p53 mutants that underlie the 
phenotypes listed in the inner circle. Each of the phenotypic effects can be attributed to almost each of 
the mechanistic properties; hence the inner blue circle can be freely rotated (Brosh and Rotter, 2009). 
 
factors, specific co-activators, histone-acetyltransferases or de-acetylases augmenting 
or repressing the expression of genes that are targeted directly by partner factors 
(Oren and Rotter, 2010). Besides p63 and p73, the first two transcription factors 
shown to interact with mutant p53 were SP1 and ETS1 (Chicas et al., 2000); 
(Sampath et al., 2001). The transcriptional complex modulated by mutant p53 and 
these transcription factors promotes pro-survival signals. 
In addition several p53 mutants have been reported to bind specific DNA structure 
with high affinity (Gohler et al., 2005), therefore suggesting that mutant p53 
specificity towards certain regulatory elements could be mediated by preferential 
binding to structural DNA motif rather than consensus sequences. 
Interactions between mutant p53 and other partners not directly linked to transcription 
have been reported to play a role in mut-p53 GOF. For example, it was found that 
mut-p53 binding to the upstream component MRe11, can disrupt ATM-mediated 
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cellular responses to double stranded DNA breaks (Song et al., 2007; Song and Xu, 
2007) while the interaction with topoisomerase I, increasing aberrant homologous 
DNA recombination and mutagenic DNA rearrangement, contributes to genomic 
instability (Restle et al., 2008).  
 
Regulation of mutant p53 stability 
In contrast to the plethora of information available for wild type p53, the regulation of 
mutant p53 stability and activity, and the status of its post-translational modifications, 
are much less characterized (Brosh and Rotter, 2009). 
In opposition to the wild type counterpart, mutant p53 is often found at high levels in 
tumors (Bartek et al., 1991); in fact, immunohistochemical detection of p53 in tissue 
sections is commonly used as a surrogate for detecting TP53 missense mutation and 
can provide prognostic and predictive informations (Soussi and Beroud, 2001). 
Moreover, high mutant p53 protein levels are thought to be responsible for most of its 
oncogenic functions, since its depletion reduces the aggressive features associated to 
GOF (Muller and Vousden, 2013) and conversely, its precocious stabilization in 
knock-in mice is associated with enhanced aggressiveness (Suh et al., 2011; Terzian 
et al., 2008).  
Interestingly, in mutant p53 knock-in mice models, no stabilization of the protein is 
observed in normal tissue, but mut-p53 is found accumulated exclusively in tumors 
(Lang et al., 2004; Olive et al., 2004). Similarly, in patients with Li-Fraumeni 
syndrome, mutant p53 does not accumulate in normal tissues, but only in tumors. 
Interestingly, when mutant p53 knock-in mice were crossed into a Mdm2-null 
background, the mut-p53 protein was stabilized in nearly all normal tissues (Terzian 
et al., 2008), suggesting that the same mechanisms regulating the wild type protein are 
responsible for maintaining mutant p53 at low levels in normal (but not tumor) 
tissues.  
A clue to the nature of mutant p53 stabilization may be provided by the observation 
that in primary cells derived from mutant p53 knock in mice, the unstable protein can 
be stabilized by genotoxic stress very much like wt-p53 (Lang et al., 2004), however, 
mutant p53 is incapable of transactivating Mdm2 (Oren and Rotter, 2010), thus 
breaking the regulatory feedback loop. 
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These results strongly suggest that p53 mutations alone are insufficient for mutant p53 
accumulation, but additional events occurring in tumors are required to release mut-53 
from Mdm2-mediated degradation. For example, since tumor cells experience chronic 
DNA damage and other alterations, it is possible that the resulting signaling events, 
normally aimed at activating the endogenous wt-p53 and preventing cancer cell 
proliferation, could also promote mut-p53 protein stability, resulting in cancer 
promotion. 
Interestingly, Mdm2 isoforms A, B, and C, are frequently found overexpressed in 
high grade tumors indicating a role of such isoforms in tumorigenesis (Bartel et al., 
2002). A common feature of these isoforms is the lack of p53 binding domain, while 
they retain the ability to bind full length Mdm2 (Fridman et al., 2003). A recent work 
established a role of Mdm2-B in promoting mutant p53 accumulation and GOF, 
through the inhibition of Mdm2-mediated mutant p53 degradation (Zheng et al., 
2013).  
Other ubiquitin ligases that target wild type p53 regulate also mutant p53 stability, 
such as C-terminus of HSP70-interacting protein (CHIP) (Esser et al., 2005; 
Lukashchuk and Vousden, 2007). CHIP- and Mdm2-mediated ubiquitination of 
mutant p53 is counteracted by the chaperone HSP90, which binds mutant p53 
increasing its stability (Esser et al., 2005; Li et al., 2011). Notably, HSP90 is found 
overexpressed in tumors (Kamal et al., 2003). 
 
Mutant p53 oncogenic properties 
Mutant p53 plays a fundamental role in cellular transformation as demonstrated in 
both human and mouse models: introduction of mut-p53 forms can, indeed, transform 
p53-null cells and endow them with an increased ability to form colonies in soft agar 
and tumors in mice (Dittmer et al., 1993). Conversely, down-regulation of 
endogenous mutant p53 renders cancer cells less tumorigenic (Bossi et al., 2008). 
Mutant p53 forms seem to take part in almost every aspect of cancer development, 
including most of the Hanahan and Wienberg hallmarks (Hanahan and Weinberg, 
2011). 
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In particular several studies investigated the role of mutant p53 in promoting 
migration and invasion of tumor cells by controlling pathways that are involved in the 
regulation of these phenotypes.  
Indeed, mutant p53 was found to enhance the activation of EGFR/integrin signaling 
and modulating TGFβ pathway thus facilitating cell migration and invasion (Adorno 
et al., 2009; Dhar et al., 2008; Muller et al., 2009). This is achieved by two non-
mutually exclusive mechanisms of inhibition of p63 anti-metastatic functions. 
Furthermore, mutant p53 can induce EMT in several cancer models, including 
prostate, lung, and breast cancer, thus allowing invasiveness: mutant p53 supports  
EMT transition modulating Slug or Twist activity (Kogan-Sakin et al., 2011; Wang et 
al., 2009), or by suppressing the anti-invasive gene CCN-5/WISP2 (Dhar et al., 2008). 
In addition, it has also been demonstrated a role of mutant p53 in coordinating three-
dimensional growth: mutant p53 depletion in aggressive breast cancer-derived cells 
reverts malignant-appearing cells into more benign cells, which form acinous-like 
structures (Freed-Pastor et al., 2012). 
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Ribosome biogenesis 
 
Ribosome biogenesis is a very important and complex process in the life cycle of a 
cell: it requires the coordinated action of all three RNA polymerases to transcribe four 
types of different rRNAs, approximately 79 ribosomal proteins, and hundreds of 
ribosome assembly factors. In yeast, it has been estimated, that ribosome biosynthesis 
accounts for up to 60% of total transcriptional activity and the synthesis of mRNA 
encoding ribosomal proteins accounts for 50% of all RNA Polymerase II initiation 
events (Warner, 1999). 
 
 
Figure 6. Mammalian ribosome biogenesis. Ribosome biogenesis consists of rRNA synthesis, rRNA 
processing and ribosome maturation. RNA Pol I transcribes a 14 kb-long, poly- cistronic 47S rRNA 
precursor that contains 18S, 5.8S, and 28S rRNAs. RNA Pol II transcription facilitates the synthesis of 
79 ribosomal L- and S-proteins, a large cohort of small nucleolar (sno)RNAs, and > 200 mRNAs 
encoding non-ribosomal nucleolar factors, including kinases, helicases, nucleases, and GTPases. In 
addition, 5S rRNA is produced by RNA Pol III. The orchestrated activity of all three RNA polymerases 
ensures the correct transcription, processing, and modification of rRNA and its assembly into 40S and 
60S ribosomal subunits that compose functional 80S ribosomes in the cytoplasm (Eichler and Craig , 
1994 ; Boisvert et al. , 2007 ). 
 
Eukaryotic ribosomes (80S) are composed of two distinct subunits, small (40S) and 
large (60S), respectively. The small 40S subunit contains a single 18S rRNA and 33 
ribosomal proteins (Rabl et al., 2011), while the larger 60S subunit contains 3 
different rRNAs: 5S, 5.8S and 28S, and 46 ribosomal proteins (Klinge et al., 2011). 
The nucleolus is the cellular compartment where most of ribosome biogenesis takes 
place. In the nucleolus RNA polymerase I (Pol I) transcribes a single 47S rRNA 
precursor (pre-rRNA) (Roeder and Rutter, 1970), which is then modified and cleaved 
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to obtain mature 18S, 5.8S and 28S rRNA. 5S rRNA is transcribed independently in 
the nucleous by RNA polymerase III, after processing the mature 5S rRNA is 
imported in the nucleolus as a ribonucleoprotein complex (Lee and Nazar, 2003). 
rRNA maturation process requires chemical modifications, cleavage steps, assembly 
to ribosomal proteins and transport through different cellular compartments to obtain 
mature ribosomes (fig. 6). 
The first step of this highly organized pathway is the covalent modification of pre-
rRNA: in mammals more than 200 nucleotides are modified in methylated sugars, 
pseudouridines and methylated bases (Maden, 1990); these modifications are carried 
out by small nucleolar ribonucleoparticles (snoRNPs) most of which are guided to the 
site of RNA modification by base pairing with small nucleolar RNAs (snoRNAs) 
(Lafontaine and Tollervey, 1998). These modifications are important for translation 
performance and fidelity, and binding of ligands to ribosomes, such as tRNA 
(Mullineux and Lafontaine, 2012). In addition, some snoRNAs (e.g. U3, U8, U17, 
U22 in mammals) are involved in pre-rRNA processing. 
In the pre-rRNA transcript, mature rRNAs are separated by two internal transcribed 
spacers, ITS1 and ITS2, and are flanked by two external transcribed spacers, the 5‟ 
ETS and 3‟ ETS.  The removal of external and internal spacer sequences proceeds 
through an ordered series of endo- and exonucleolytic cleavages at about 10 sites in 
the pre-rRNA, with alternative processing pathways (Fig. 7). 
 
 
Figure 7. Pre-rRNA processing pathway in mammals. ETS and ITS are external and internal 
transcribed spacers, respectively (Liang and Crooke, 2011). 
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The primary transcript, the 47S pre-rRNA, is initially cleaved at both ends of the 
molecule, generating the 45S precursor. This intermediate rRNA is further processed 
by at least two alternative pathways. These pathways differ mainly in kinetics and 
order of cleavage, and can vary according to species, cell type, physiological and 
developmental stages, and disease state. 
In the first pathway for example, the 41S pre-rRNA is generated after the complete 
removal of 5‟-ETS from the 45S pre-rRNA, and subsequently cleaved at the ITS1. 
This late cleavage generates the 32S pre-rRNA and the 18S pre-rRNA, which is 
further modified to generate mature 18S rRNA. 32S pre-rRNA undergoes other 
additional cleavages, mainly in the ITS2, to finally generate mature 5.8 and 
28SrRNAs (Mullineux and Lafontaine, 2012). 
More than 300 proteins have been described to be involved and assist ribosome 
biogenesis directly or indirectly. In particular, hundreds of factors assist and drive pre-
rRNA during its maturation process. A recent screening identified 286 proteins 
required for rRNA processing in Hela cells, many of them with yeast homologues, 
highlighting the evolutionary conservation of this key process across eukaryotes 
(Tafforeau et al., 2013). Most of these proteins associate with 47S pre-rRNA to 
generate 90S ribonucleoparticle (RNP). 
Pre-rRNA particles processing begins with the cleavage of the large 90S RNP 
complex within the ITS1 to generate pre-40S and pre-60S particles. 
After ITS1 cleavage in the nucleus, pre-40S particles are rapidly exported to the 
cytoplasm where last maturation steps generate mature 40S ribosomal subunits. The 
nuclear export of pre-40S requires Crm1 (Thomas and Kutay, 2003) and ribosomal 
protein Rps15p through a direct or indirect interaction with the nuclear transport 
machinery (Leger-Silvestre et al., 2004). In the cytoplasm the kinase hRio2 is 
required for the conversion of pre-40S in mature 40S particle (Rouquette et al., 2005). 
Pre-60S particle maturation is instead more complex, and requires many intermediate 
steps to generate mature 5.8S and 28S rRNA. In the nucleolus about 50 non-
ribosomal proteins associate to the early pre-60S ribosomal particle: among them 
Helicases, rRNA processing and modificator factors, and GTPases that promote a 
series of RNA processing reactions (Fatica and Tollervey, 2002). During rRNA 
maturation, pre-60S ribosomal subunits move from the nucleolus to the nucleoplasm 
with major changes in protein composition. Nuclear export requires the dissociation 
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of pre-rRNA particle from most of the GTPases, and the association with the NES-
containing adapter protein Nmd3 and Mtr2, and with the export receptor 
XpoI/Crm1/exportin1.  
In the cytoplasm, most of the non-ribosomal proteins are released and pre-60S rRNAs 
particles undergo the final structural rearrangement that will convert them into 
functional ribosomes competent for translation (Nissan et al., 2002). 
 
Ribosome biogenesis and cancer 
Though the discovery that the nucleolus is the site for ribosome biogenesis can be 
dated to the 1960s, nucleoli have attracted the attention of pathologists as early as the 
late 19
th
 century.  
In 1896 the Italian pathologist Giuseppe Pianese first observed and described that 
malignant cells have hyperthrophic and irregularly shaped nucleoli. Since then a lot of 
studies have been conduced to understand whether nucleolar parameters could be 
used for diagnostic purposes or to determine the clinical output of the disease, and to 
clarify whether nucleolar alterations could be the consequence of cellular 
transformation, or the leading cause of neoplastic transformation. 
It is now accepted that enlarged nucleoli in actively proliferating cells are the result of 
increased ribosome biogenesis, indeed it has been demonstrated that all mammalian 
cells stimulated to proliferate have nucleolar hypertrophy as a result of the higher 
biosynthetic demand (Derenzini and Ploton, 1991). This observation allowed mainly 
two considerations: since nucleolar size is strongly correlated with cell proliferation 
this parameter is not useful for diagnostic purposes in tumors. On the other hand since 
proliferation is the major cause in determining the growth rate of a tumor mass and 
one of the most important prognostic factors in oncology, nucleolar size turned to be a 
parameter to predict the clinical outcome in many forms of cancer (Derenzini et al., 
2009). 
For many years the increased ribosome biogenesis observed in cancer cells has been 
considered as a mere consequence of increased biosynthetic demand due to 
uncontrolled proliferation. However many works clearly demonstrate that ribosome 
biogenesis is highly controlled and many components of the protein synthesis 
machinery are deregulated or mutated in different tumors (Ruggero and Pandolfi, 
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2003). Indeed, important oncogenes and tumor suppressors genes can influence and 
modulate ribosome biogenesis (fig. 8). 
 
 
 
FIG 8. Oncogenes and tumor suppressor genes control of ribosome biogenesis.  
Ribosome biogenesis consists of rRNA synthesis, rRNA processing and ribosome maturation. RNAPI 
transcribes poly-cistronic 47S rRNA precursor that contains 18S, 5.8S, and 28S rRNAs. RNAPII 
transcribes ribosomal L- and S-proteins, small nucleolar (sno)RNAs, and non-ribosomal nucleolar 
factors. 5S rRNA is produced by RNAPIII. The orchestrated activity of all three RNA polymerases 
ensures the correct transcription, processing, nuclear export, and assembly into 40S and 60S ribosomal 
subunits that compose functional 80S ribosomes in the cytoplasm. The tumor suppressor p53 controls 
Pol I transcriptional activity preventing the interaction between UBF and SL-1. Moreover, it inhibits 
Pol III transcription by binding to the transcription factor TFIIIB. The Rb family also plays a role in the 
inhibition of rRNA synthesis and Pol III transcription, binding to UBF and TFIIIB, respectively. 
p14ARF interacts with the Pol I transcription termination factor TTF-I, preventing its localization to 
the nucleolus and inhibiting rRNA synthesis. Oncogenes, by contrast, have the opposite effect and 
increase ribosome biogenesis. The principal enhancers of ribosome biogenesis are Myc and ERK1/2. 
Myc associates with SL-1, increasing Pol I transcription, and is also found associated with 5S rRNA 
activating Pol III transcription, whereas ERK phosphorylates and activates UBF, TIF1A, and TFIIIB. 
 
Oncogenes and tumor suppressors regulating ribosome biogenesis 
Myc. Myc is a key transcription factor that directly modulates genes involved in 
ribosome biogenesis, protein synthesis and proliferation (Schmidt, 2004), and is 
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frequently overexpressed in some tumor types such as Burkitt‟s lymphomas, 
neuroblastomas and colon carcinomas (Lin and Medeiros, 2013). 
Myc controls multiple steps in ribosome biogenesis, from the transcription of rRNA, 
ribosomal proteins and accessory factors, to the nuclear export of mature ribosomal 
subunits. 
Myc has been demonstrated to promote 18S, 28S, and 5.8S rRNAs transcription at 
different levels. Myc binds rDNA loci and activates the transcription of rRNA 
through direct binding with cofactors that are required for the recruitment of RNA pol 
I to rDNA promoters (Arabi et al., 2005), and it activates a chromatin remodeling 
program that opens chromatin structure near rDNA loci (Shiue et al., 2009). In 
addition, Myc enhances the expression and recruitment of essential RNA pol I 
cofactors: UBF (upstream binding transcription factor) and SL1 (selectivity factor 1) 
(Grandori et al., 2005).  
Myc is also involved in the transcription of 5S rRNA outside the nucleolus by a direct 
interaction with TFIII3B (Gomez-Roman et al., 2003). 
This key transcription factor regulates the expression of many ribosomal proteins of 
both large and small subunit (Kim et al., 2000) and it coordinates the transcription of 
genes encoding factors required for rRNA processing such as NOP56, BOP1, PES1, 
FBL, DKC1, NCL and NPM1 (Schlosser et al., 2003). 
Finally, Myc has been observed to regulate the machinery responsible for proper 
ribosomal translocation by promoting the expression of IPO7 and XPO1, two proteins 
regulating import and export, respectively of RPs and ribosomal subunits (Golomb et 
al., 2012). 
PI3K/AKT. The PI3-kinase (PI3K)/AKT signaling pathway plays a central role in 
modulating cell survival, proliferation and motility. This statement is supported by the 
evidence that in transformation, malignant cells develop different systems to activate 
this pathway (Vivanco and Sawyers, 2002). 
Following IGF-1 treatment,the PI3K/AKT pathway is able to stimulate rRNA gene 
expression by modulating the activity of RNA pol I transcriptional machinery. This is 
achieved by increasing pol I transcription factor SL1 occupancy in rDNA promoter 
region (James and Zomerdijk, 2004). 
mTOR. The mammalian target of rapamycin (mTOR) is a kinase that regulates 
cellular functions coordinating anabolic and catabolic processes in response to growth 
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factors and nutrients (Laplante and Sabatini, 2013). mTOR regulates ribosome 
biogenesis at different levels by promoting both rRNA transcription and processing. 
In response to nutrients, mTOR is able to promote rRNA transcription both 
stimulating the binding between the essential transcription factor TIF-IA and the 
initiation competent form of RNA pol I (Mayer et al., 2004), and promoting the 
interaction of UBF with SL1 thereby promoting Pol I activity (Hannan et al., 2003). 
mTOR is also able to stimulate the synthesis of 5S rRNA by RNA pol III facilitating 
the association of the transcription factors TFIIIB and TFIIIC with the 5S gene 
(Mayer and Grummt, 2006). 
Ras/Raf/ERK. The Ras-dependent mitogen-activated protein kinase (MAPKs) 
cascades play a key role in coordinating extracellular signals to a transcriptional 
program promoting cellular growth and malignant transformation. The importance of 
this pathway in cellular transformation in highlighted by the fact that it is frequently 
altered in human tumors, and mutations in Ras are the most common mutations in 
colon, lung, and pancreatic carcinomas (Fernandez-Medarde and Santos, 2011). 
The Ras pathway has been demonstrated to stimulate ribosome biogenesis mainly 
through its main downstream molecules MEKs and ERKs (James and Zomerdijk, 
2004; Wang and Chen, 1998), which bind and phosphorylate TIF-1A and UBF, thus 
promoting pol I rRNA transcription, and TFIIIB, thus promoting 5S rRNA synthesis 
(Felton-Edkins et al., 2003; Zhao et al., 2003). 
A crosstalk between Ras and Myc has been demonstrated: in fact, by activating 
ERKs, Ras can promote Myc stabilization by direct phosphorylation (Zhu et al., 
2008), and counteracting the inhibitory activity of GSK3β through the activation of 
PI3K-Akt pathway (Lee et al., 2008). 
RB. Rb, the product of the retinoblastoma-associated gene RB1, has a major rolei n 
the regulation of cell cycle progression through its capability to arrest cells in G1 
phase and to prevent uncontrolled cell proliferation (Chau and Wang, 2003). The 
variety of human cancers in which the retinoblastoma protein Rb is inactivated 
reflects its importance as tumor suppressor, indeed pRb is frequently mutated or 
expressed at low levels in several tumors such as retinoblastoma, osteosarcoma, lung, 
prostate, bladder and breast carcinomas (Piva, 2014). 
Besides its role in inhibiting cell cycle progression, Rb has been demonstrated to 
regulate ribosome biogenesis through its interaction with UBF and TFIIIB, thereby 
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inhibiting RNA pol I and pol III activity, respectively (Cavanaugh et al., 1995; White 
et al., 1996). Remarkably, during cell cycle progression, phosphorylated Rb actively 
induces rRNA transcription, so Rb knock-out mice display reduced pol III activity 
(White et al., 1996). 
INK4A-ARF. The INK4A-ARF locus encodes for the tumor suppressors p16
INK4A
 
and p14
ARF
 that activate the growth suppressor functions of Rb and p53, respectively. 
Giving its role in modulating two important tumor suppressive pathways, deletions of 
the INK4A-ARF locus is a frequent event in tumors (Ozenne et al., 2010). 
p14
ARF 
is able to inhibit ribosome biogenesis by direct interaction with 
Nucleophosmim (NPM). NPM is a chaperone able to control nucleoplasm nucleolar 
shuttling of the RNA polymerase I transcription termination factor, TTF-I. ARF binds 
and inhibit NPM functions promoting its ubiquitination and subsequent proteosomal 
degradation (Lessard et al., 2010).  
p53. In addition to its well established role in promoting cell cycle arrest and 
apoptosis, the tumor suppressor p53 has been reported to inhibit ribosome biogenesis 
at different stages. 
p53 over-expression in Hela cells results in a strong reduction in RNA pol I activity 
by interfering with the formation of the initiation complex between SL-1, UBF, and 
pol I (Zhai and Comai, 2000). Moreover p53 inhibits 5S rRNA transcription by RNA 
pol III trough binding to the transcription factor TFIIIB.  
Recently, p53, once activated has been observed to directly negatively regulate 
expression of U1 and U6 snoRNAs by both RNA pol I and pol III (Krastev et al., 
2011).  
 
Ribosome biogenesis and p53 
For many years the function of the nucleolus has been thought to be limited to the 
production of the ribosomal subunits. However, recent studies have challenged this 
view by showing that among the 4500 proteins associated with the nucleolus only 
30% are directly involved in ribosome biogenesis (Ahmad et al., 2009). These studies 
strongly supported the concept of a “multifunctional nucleolus” proposed by Thoru 
Pederson in 1998, demonstrating that besides ribosome biogenesis, the nucleolus is 
involved in controlling other cellular functions (Pederson, 1998). Some of these 
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additional functions link the nucleolus to the regulation of cell cycle progression, 
induction of apoptosis and others (Boisvert et al., 2007). 
The proposed mechanism by which the nucleolus can integrate different signals to 
trigger diverse cellular outcomes is by modulating the activity of regulatory proteins 
essential for these processes. Proteomic studies have indeed revealed that the protein 
content of the nucleolus is highly dynamic and modified upon stress conditions, thus 
allowing a crosstalk between altered nucleolar functions and cell responses (Boulon et 
al., 2010). 
The tumor suppressor p53 is deeply linked to the nucleolar status. A landmark study 
by Rubbi and Milner even revealed that stabilization and activation of the p53 
pathway by radiation-induced nuclear DNA damage occurs only when irradiation also 
affects nucleolar integrity (Rubbi and Milner, 2003), thus indicating the nucleolus as a 
central hub in controlling p53 functions. 
In line with this observation, the nucleolus has been proposed to workas a stress 
sensor responsible both for maintaining low p53 levels under physiological 
conditions, and to promote p53 accumulation as soon as nucleolar functions are 
impaired (Rubbi and Milner, 2003). 
 
Mechanism of p53 activation upon ribosomal stress 
The key downstream event in promoting p53 accumulation after ribosomal stress is 
probably the inactivation of the p53-inhibitor Mdm2 by direct binding of ribosomal 
proteins (RPs). This surveillance mechanism has been defined as the “RPs-Mdm2-p53 
stress response pathway” (Deisenroth and Zhang, 2010). In principle, conditions that 
disrupt ribosome biogenesis at different levels are postulated to create a pool of 
unused ribosomal proteins that are free to interact with other molecules, in this 
specific case Mdm2, thus altering their functions. Indeed in recent years, many 
ribosomal proteins, including RPL5, RPL11, RPL23, RPL26, RPS3, RPS7, RPS14, 
RPS25, RPS26, RPS27/L, have been reported to bind and inhibit Mdm2 functions 
mostly in vitro and in tissue culture (Shcherbik and Pestov, 2010). 
Mechanistically, since most of these ribosomal proteins bind the central region of 
Mdm2, they are thought to create a conformational block that prevents the transfer of 
ubiquitin from the C-terminal RING finger domain to the N-terminal p53 binding site. 
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In support of this thesis, it was demonstrated that RPs-bound Mdm2 retains the ability 
to interact with p53, but loses its ubiquitin ligase activity (Dai and Lu, 2004; Jin et al., 
2004). 
A recent work by the group of Yanping Zang addressed the in vivo role of RPs-Mdm2 
interactions. The starting observation was that many cancer-associated Mdm2 
mutations that target the central zinc finger domain, including point mutations in 
conserved zinc-coordinating cysteines, disrupt Mdm2 binding toRPL5 and RPL11, 
thus compromising the ability of p53 to be accumulated in response to ribosomal but 
not genotoxic stress (Lindstrom et al., 2007). 
They generated mice carrying such a cancer associated mutation (Mdm2
C305F
) in the 
Mdm2 zinc finger and analyzed the effect of uncoupling the RP-Mdm2-p53 axis in a 
model of c-MYC induced tumorigenesis: they demonstrated that in cells derived from 
Mdm2
C305F
 knock-in mice (expressing a functional Mdm2 that cannot bind RPL5 and 
RPL11) p53 responds normally to DNA damage, but is not stabilized by nucleolar 
stress. These mice displayed strongly increased Myc-induced lymphomagenesis 
(Macias et al., 2010). 
This work established the central role of RPL5 and RPL11, among the many other 
ribosomal proteins, in promoting p53 activation upon aberrant ribosome biogenesis. 
Therefore, the RP-MDM2-p53 pathway can be considered tumor suppressive, 
restraining proliferation of cells with defective or uncontrolled ribosome biogenesis 
(de Las Heras-Rubio et al., 2013). 
 
Disruption of rRNA synthesis activates p53 
Perturbation at any step in the process of ribosome biogenesis, such as rRNA 
transcription, early and late processing, and ribosomal proteins imbalance, has been 
demonstrated to contribute to nucleolar stress, leading to accumulation and activation 
of the p53 tumor suppressor protein (fig. 9).   
Inhibition of de novo rRNA synthesis is an established mechanism for inducing 
ribosomal stress and to activate RP-MDM2-p53 pathway. 
A commonly used approach to inhibit rRNA production is treatment with drugs that 
inhibit the activity of RNA Pol I, or deplete the available pool of nucleotides for new 
rRNA synthesis.   
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The most widely used compounds for this purpose are Actinomycin D (ActD) and 5-
Fluorouracil (5-FU). ActD is an antineoplastic compound that at low concentrations 
(<10nM) specifically disrupts ribosome biogenesis by intercalating into the GC-rich 
regions of rDNA to inhibit Pol I-mediated transcription of nascent rRNA (Perry and 
Kelley, 1968, 1970; Sobell et al., 1971). Most of the studies demonstrating the RP-
MDM2-p53 axis use this agent to generate ribosomal stress and activate p53. 
 
 
 
Figure 9. Perturbations to ribosome biogenesis trigger a p53 response. Dysfunction at discrete 
phases of rRNA transcription, processing, and assembly during ribosome biogenesis are known to lead 
to p53-mediated responses. Select RPs are known to transduce nucleolar stress signals to p53, 
particularly in response to attenuation of rRNA transcription. (Deisenroth and Zhang, 2010)  
 
5-FU is another commonly used chemotherapeutic compound that alters ribosome 
biogenesis, activating the RP-Mdm2-p53 pathway (Sun et al., 2007). 5-FU, as uracil 
analogue, is incorporated into nascent rRNA and completely blocks rRNA synthesis 
(Longley et al., 2003). 
Accumulation and activation of p53 by inhibition of rRNA transcription has been also 
demonstrated by altering the expression of key regulatory elements. For example, 
siRNA depletion of components of RNA Pol I machinery, such as transcription factor 
TIF-1A, has been demonstrated to trigger loss of nucleolar structure, reduced rRNA 
transcription, and activation of the p53 pathway (Yuan et al., 2005). 
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Disruption of rRNA processing activates p53 
Alterations in rRNA processing can lead to accumulation of unprocessed intermediate 
transcripts that can retard subunit assembly, therefore inducing nucleolar stress. 
Bop1 is a nucleolar processing factor required for the cleavage of the ITS1 and ITS2 
as well as the 3‟-ETS of rRNA(Strezoska et al., 2002). The expression of a dominant 
negative form of Bop1 in mouse cells blocks 28S and 5.8S rRNA processing, leading 
to impaired ribosome large subunit assembly, and p53-dependent inhibition of cell 
cycle progression (Pestov et al., 2001). Bop1 together with Pes1 and WDR12 forms a 
nucleolar complex termed PeBoW complex. Similar to Bop1, depletion of WDR12 
also induces rRNA processing defects and a p53 dependent cell cycle arrest (Holzel et 
al., 2005), thus suggesting that disruption of this functional complex involved in 
rRNA processing activates the RP-Mdm2-p53 checkpoint. 
 
Ribosomal proteins imbalance activates p53 
There are many clinical manifestations caused by imbalance in ribosomal proteins 
production, globally named ribosomepathies. These diseases are associated with 
mutations or haploinsufficiency in various RP genes, leading to impaired ribosome 
biosynthesis. For instance one of the most frequent ribosome biogenesis disease is 
Diamond Blackfan anemia (DBA), a genetic disease in which mutations in several 
different RP genes cause a congenital bone marrow failure syndrome with a striking 
erythroid defect (Narla and Ebert, 2010). In addiction with chronic anemia and 
congenital abnormalities, DBA patients also harbor a predisposition to develop 
different forms of cancer (Freed et al., 2010). 
It is commonly accepted that functional ribosome biogenesis requires a consistent 
supply of ribosomal proteins, so an imbalance in the stoichiometric ratio of RPs can 
alter the assembly of 40S or 60S subunits, inducing ribosomal stress (Deisenroth and 
Zhang, 2010) thereby activating p53. 
It has been consistently reported that disruption of 60S ribosome biogenesis  alters 
nucleolar structure, inducing the release in the nucleoplasm of RPs, Mdm2 inhibition, 
and p53 accumulation and activation (Sun et al., 2010). 
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Interestingly, a different mechanism for p53 accumulation upon inhibition of 40S 
ribosome biogenesis has been described. Indeed altered 40S ribosome biogenesis has 
no effect on nucleolar integrity, although p53 induction is still mediated by RPL11. 
Rather, upon impairment of 40S ribosome biogenesis, despite a decrease in global 
translation, cells upregulate the translation of mRNAs with a polypyrimidine tract at 
their 5‟ transcriptional start sites (5‟-TOP mRNAs). Among those mRNAs is that 
encoding RPL11, thus providing a pool of L11 protein able to bind and inhibit Mdm2 
functions (Fumagalli et al., 2009). 
 
GTPBP4 
GTPBP4, also known as Nog1, NGB or CRFG, is a nucleolar GTP-binding protein of 
the Obg family. Obg family proteins are characterized by a G-domain and have been 
implicated in diverse cellular processes, including stress response, chromosome 
replication, and differentiation (Lapik et al., 2007).   
GTPBP4 was initially described as the product of the chronic renal failure gene 
CRFG, a gene expressed in the outer medulla of the kidney, which is lost with renal 
disease or injury (Laping et al., 2001). Subsequently, other studies demonstrated that 
GTPBP4 is involved in ribosome biogenesis, and in particular it is an essential factor 
required for biogenesis of the 60S ribosomal subunit (Jensen et al., 2003). 
GTPBP4 is a 634 amino acid protein. At the N-terminus of the protein there is a 
nuclear localization signal and a GTP binding domain, while at the C-terminus it 
contains coiled-coil domains. Moreover, GTPBP4 has five sequence motifs, G1 to 
G5, which are conserved in the GTPase superfamily. Apart from these characteristic 
motifs, the amino acid sequence of the protein differs substantially from other well 
characterized G-proteins suggesting the existence of a new subfamily of GTP-binding 
proteins (Lee et al., 2007). 
GTPBP4 has been demonstrated to be linked to ribosome biogenesis in the early 
2000s. In T. Brucei, GTPBP4 ortholog has been identified as a nucleolar protein (Park 
et al., 2001), and further studies in yeast and trypanosomes demonstrated that in these 
organisms GTPBP4 is essential for the biogenesis of 60S ribosomal subunits. Indeed, 
yeast cells depleted of GTPBP4 or harboring temperature sensitive alleles of the gene 
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display defects in pre-rRNA processing and in the release of nascent pre-60S subunits 
from the nucleolus (Kallstrom et al., 2003; Saveanu et al., 2003). 
Proteomic analysis in yeast showed the association of GTPBP4 ortholog with multiple 
components of pre-60S ribosomes (Fuentes et al., 2007; Lebreton et al., 2006) 
suggesting a role of GTPBP4 in promoting different steps in ribosome biogenesis. 
These studies demonstrated that GTPBP4 accompanies the pre-60S ribosomal 
precursor in the late stages of maturation, shuttling between nucleoplasm and 
cytoplasm. In the cytoplasm, GTPBP4 is released from nascent 60S subunit along 
with other shuttling proteins, and is rapidly re-imported in the nucleus (Pertschy et al., 
2007). 
GTPBP4 functions seem to be regulated by nutrient availability. Indeed mTOR, 
beside its known involvement in regulating early stages of ribosome maturation in the 
nucleolus, has been reported in yeast to regulate also late stages of ribosome 
biogenesis via GTPBP4. Upon nutrient starvation, or mTOR pharmacological 
inhibition (Rapamycin treatment), GTPBP4 is first tethered in the nucleolus and then 
is transcriptionally reduced leading to cessation of ribosome maturation (Honma et 
al., 2006).  
Interestingly, a further link between nutrient availability and GTPBP4 functions has 
been recently provided. In C. elegans knockdown of the GTPBP4 ortholog resulted in 
smaller broodsize, slower growth, increased lifespan, and more fat storage. Since 
TOR is involved in regulating lifespan and fat storage in this animal model, the 
authors proposed GTPBP4 as an important player in the insulin/IGF pathway (Kim et 
al., 2014). 
 
Targeting ribosome biogenesis in cancer therapy 
Classical DNA-damage chemotherapy, being mutagenic, can cause secondary tumors, 
especially in survivors of childhood cancers; therefore, alternative drugs are of 
particular interest. Since ribosome biogenesis is a critical target of classical 
chemotherapy, drugs that specifically inhibit rRNA synthesis without genotoxic side 
effects would be desirable. Indeed, in the last years some steps in ribosome biogenesis 
have been reported to be potentially therapeutically targeted (Burger and Eick, 2013). 
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RNA polymerase I, for example, has been considered as a therapeutic target in cancer, 
and molecules have been designed to target specifically rDNA transcription. CX-
3543, for example, is a molecule that disrupts the interaction of the nucleolar 
processing factor nucleolin with rDNAG-quadruplex complexes in the nucleolus and 
induces apoptosis in cancer cells (Drygin et al., 2009). Another molecule, CX-5461 
has been reported to selectively kill B-lymphoma cells in vivo while maintaining a 
viable wild type B cell population. The therapeutic effect of CX-5461 is achieved by 
blocking the recruitment of SL1 to Pol I promoter, leading to nucleolar disruption and 
activation of p53 dependent apoptotic signaling (Drygin et al., 2011).Thus, non-
genotoxic inhibition of Pol I transcription could be an important therapeutic strategy 
for cancer specific activation of p53 in cancer cells. 
The nucleolar protein Nucleophosmin (NPM1) promotes rRNA processing during 
ribosome biogenesis, and its expression is found frequently altered in tumors; notably, 
overexpression of NPM drives leukemia initiation (Grisendi et al., 2006; Vassiliou et 
al., 2011). Two small compound inhibitors have been found for NPM1, NSC348884 
and avrainvillamide. The first molecule, NSC348884, inhibiting NPM1 
oligomerization, leads to p53 activation. This compound has been reported to 
synergize with the cytotoxicity of doxorubicin in various cancer cells (Qi et al., 2008). 
The second compound, avrainvillamide, is an alkaloid that was identified in an 
affinity screen with NPM1. Avrainvillamide also stabilizes p53 and induces apoptosis 
in cancer cells (Wulff et al., 2007). 
These encouraging results emphasize that inhibition of ribosome biogenesis can be a 
promising approach for cancer therapy; within this area, a better understanding of the 
molecular mechanisms involved and the identification of novel potential targets might 
help to broaden available therapeutic options. 
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PART 1: Exploring the mechanism of wild type p53 accumulation 
upon GTPBP4 depletion 
 
The p53 tumor suppressor protein is a transcription factor capable of sensing a wide 
range of stress signals, and coordinating a complex cellular response that can lead to 
cell cycle arrest, DNA repair, apoptosis or senescence (Vousden and Lu, 2002). 
p53 activation and function requires a complex repertoire of posttranslational 
modifications and protein-protein interactions that are essential to integrate stress 
signals to a proper cellular outcome (Kruse and Gu, 2009). 
Many years of research have now clearly shown that the biology of p53 is very 
complex, and that p53 is a highly interconnected protein, interfacing with different 
pathways (Collavin et al., 2010). Indeed, more than 150 p53-binding proteins have 
been described, and the list is increasing.  
To gain novel insights on p53 interaction profile, our laboratory took a phylogenetic 
perspective, reasoning that the identification of new p53 interacting proteins in a 
simpler organism, such as D. melanogaster, could help identify conserved interactions 
of p53 and p53-family proteins in man. Using a genome-scale in vitro expression 
cloning approach, 91 previously unreported interactors of Drosophila p53 were 
identified. Looking for evolutionary conservation of these interactions, 41 mammalian 
orthologues were tested for binding to human p53 and p53 related proteins p63 and 
p73. Novel identified p53 interacting proteins were then tested in a functional screen 
in cells treated with DNA damaging drugs or Nutlin, leading to the validation of five 
such interactors as potential modulators of p53-dependent growth arrest (Lunardi et 
al., 2010). 
Among the five novel functionally validated p53 interactors, GTPBP4, a monomeric 
GTPase that plays a crucial role in 60S ribosome biogenesis, was of particular 
interest. The interest derived from the observation that GTPBP4 was the only 
identified p53 interactor that did not bind p63 or p73, and that its depletion by siRNA 
induced accumulation and activation of the p53 protein.  
Given the role of GTPBP4 in ribosome biogenesis, and the well-established link 
between altered ribosome biogenesis and p53 functions, further experiments were 
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performed to explore whether GTPBP4 depletion could affect p53 stability via the 
nucleolar stress response pathway.  
All currently known mechanisms linking altered ribosome biogenesis to p53 
activation rely directly or indirectly on the binding of ribosomal proteins to Mdm2, 
thus leading to its inhibition and consequent p53 stabilization (Hein et al., 2013). 
Interestingly, GTPBP4 depletion did not alter nucleolar structure and p53 
accumulation did not correlate with increased protein half-life in the cell model used 
(fig. 10), thus suggesting the possible involvement of an alternative mechanism 
(Lunardi et al., 2010). 
Considering that Mdm2 is not conserved in Drosophila, GTPBP4 might therefore be 
an ancient point of intersection between ribosome biogenesis and the p53 pathway. To 
dissect this potentially novel regulatory axis, we therefore decided to analyze in more 
detail the mechanism of p53 accumulation upon GTPBP4 depletion. 
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Figure 10. GTPBP4 knockdown does not alter nucleolar structure and does not promote p53 
stabilization.    
A) GTPBP4 knockdown does not affect localization of key nucleolar proteins. Immunofluorescence 
analysis is shown for GTPBP4, Nucleolin, and UBF in U2OS cells transfected for 48 hours with either 
control or GTPBP4 siRNA. The same proteins were analyzed in U2OS cells treated with 5 nM 
Actinomycin D for 12 hours. Nuclei were counterstained with Hoechst. B) GTPBP4 knockdown does 
not induce p53 stabilization. Quantification is shown of the ratio of p53 to Hsp90 (measured by 
densitometry on Western blots) in HCT116 WT cells transfected with GTPBP4 siRNA (solid 
diamonds) or control siRNA (open circles) for 48 hours and treated for the indicated times with 50 μM 
Cycloheximide (CHX). Data are means ± SD for three independent experiments. C) Representative 
Western blot used for the analysis of p53 half-life. To obtain a comparable p53 signal, the gel was 
loaded with 15 μg lysate of control siRNA samples (Left), and 7.5 μg lysate of GTPBP4 knockdown 
samples (Right). Immunoblotting for GTPBP4 confirmed efficient knockdown of the endogenous 
protein (Lunardi et al., 2010). 
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PART 1: RESULTS 
 
Generation of HCT116 cell line inducible for GTPBP4 silencing 
To analyze the mechanism of p53 accumulation upon GTPBP4 depletion, we decided 
to generate stable cell lines for inducible knock-down of GTPBP4 in the HCT116 
colon cancer cell model (bearing wild-type p53). Such system allows GTPBP4 
depletion without the side effects of transient siRNA transfection. 
HCT116shC and HCT116shGTPBP4 cell lines were generated through infection of 
lentiviral vectors expressing the corresponding Tet-inducible shRNAs (purchased 
from Thermo Scientific), and upon treatment with doxycycline, effective GTPBP4 
silencing and p53 accumulation were verified by western blot. As shown in fig. 11A, 
48 hours of doxycycline treatment reduced GTPBP4 expression, and as expected, 
GTPBP4 depletion correlates with a marked p53 accumulation. Treatment with Doxy 
of the HCT116shC cells resulted in no alteration in GTPBP4 and p53 levels, thus 
confirming the specificity of GTPBP4 depletion on p53 accumulation, and also 
excluding non specific effects of doxycycline on p53 (or GTPBP4). 
Induced cells were also stained with propidium iodide (PI) and were subjected to 
FACS analysis (fig. 11B). In these cells, GTPBP4 depletion promoted a significant 
reduction in the proliferation rate (measured as the percentage of cells in S- and G1-
phase), thus suggesting that increased p53 is active. 
To further characterize this cellular system, we analyzed p53 and GTPBP4 mRNA 
levels by RT-qPCR in the same conditions. As expected, doxycycline treatment 
resulted in a strong reduction in GTPBP4 expression while p53 mRNA levels 
remained unaffected (fig. 11C). 
All these results are in line with our previous observations (Lunardi et al., 2010), so 
this inducible cellular system represents a reliable tool to study the mechanism of p53 
accumulation upon GTPBP4 depletion.  
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Figure 11. Generation of HCT116 cell line inducible for GTPBP4 silencing. 
A) GTPBP4 depletion promotes p53 accumulation. HCT116shC and shGTPBP4 cells were treated for 
48 hours with doxycycline (1μg/ml) or left untreated, and subjected to western blot analysis. GTPBP4 
was blotted to confirm knockdown and Actin was detected as loading control. B) GTPBP4 depletion 
inhibits cell proliferation. HCT116shC and shGTPBP4 cells were treated as in A. Cells were analyzed 
by flow cytometry and DNA content was evaluated by Propidium Iodide (PI) staining. Cell cycle 
analysis was performed with FlowJo software. C) GTPBP4 depletion does not affect p53 mRNA 
levels. HCT116shGTPBP4 cells were treated as in A. GTPBP4 and p53 expression levels were 
measured by RT-qPCR. Data were normalized to GAPDH, and compared to expression levels in 
untreated cells.     
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Analysis of p53 translation in GTPBP4 depleted cells 
Since previous experiments from our laboratory excluded the involvement of 
GTPBP4 in controlling p53 stability or p53 mRNA expression, we asked whether 
GTPBP4 depletion might promote p53 accumulation at the translational level. 
There are in fact examples of ribosomal proteins controlling p53 translation:  indeed 
RPL26 and nucleolin were found to bind the 5‟ untranslated region (UTR) of p53 
mRNA and to control p53 with translation and induction after DNA damage (Takagi 
et al., 2005).  
To determine whether GTPBP4 depletion could increase p53 levels by promoting its 
mRNA translation, we used two experimental approaches. 
In one approach, we labeled newly synthesized proteins with [
35
S]methionine. 
HCT116shGTPBP4 cells were treated for 48 hours with doxycycline or left untreated, 
and then incubated in medium with labeled methionine and cysteine in the presence of 
proteasome inhibitor. After 1 hour, p53 and HSP90 (used as a control), were 
immunoprecipitated and analyzed by SDS-PAGE and autoradiography. As shown in 
fig. 12A, no significant differences in the rate of p53 protein synthesis were detected 
with or without doxycycline treatment (i.e. GTPBP4 depletion). 
In an alternative approach, in collaboration with Dr. Quattrone from the University of 
Trento, we analyzed the polysome distribution of p53 mRNA in cells depleted for 
GTPBP4. Polysomes profiles of untreated and doxycycline induced 
HCT116shGTPBP4 cells were generated by sucrose-gradient centrifugation and are 
shown in fig. 12B and C. The first observation is that doxycycline treatment strongly 
impacts on sub-polysomal and light polysomal fractions (see fractions 7 and 8); this 
might be due to the growth arrest of these cells (see Fig. 11B), or might indicate that 
GTPBP4 depletion is altering ribosome neo-synthesis.  
We then analyzed by RT-qPCR the distribution of p53 and GAPDH mRNAs on 
polysomal fractions. As shown in fig. 12D, doxycycline treatment does not 
significantly affect p53 mRNA distribution on polysomial fractions; in particular it 
does not increase p53 mRNA loading on larger polysomes, thus suggesting that 
GTPBP4 depletion does not increase p53 translation. 
These two different approaches lead to the conclusion that GTPBP4 depletion does 
not promote increased p53 translation, at least in our inducible shRNA cellular model. 
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Moreover, the polysomial analysis allowed us to speculate that at the timing of p53 
accumulation ribosome biogenesis might be already altered by GTPBP4 depletion, 
even if no effects on global protein synthesis are observed (See Fig. 12A). 
 
GTPBP4 depletion promotes p53 stability 
The above results prompted us to reconsider our initial hypothesis that GTPBP4 
might be a regulator of p53 translation. 
Thus, since we found no differences in transcription and translation of p53 mRNA 
upon GTPBP4 depletion, we had to go back and re-examine the possible role of p53 
stabilization. 
We therefore analyzed p53 half-life with a series of meticulous cycloheximide 
experiments in the inducible HCT116shGTPBP4 cell line. 
In contrast to previous results from transient siRNA transfection, in this cellular 
system GTPBP4 depletion promotes a reproducible increase in p53 stability (fig. 13A 
and fig. 13B). Specifically, p53 half-life increased from about 30 to 60 minutes upon 
GTPBP4 knockdown. 
These results completely subverted our initial model, and led us to reconsider the 
possible pathways leading to p53 accumulation after GTPBP4 depletion. 
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Figure 12. GTPBP4 depletion does not increase p53 translation.  
A) GTPBP4 depletion does not increase p53 neosynthesis. HCT116shGTPBP4cells were treated as 
indicated in fig. 11, pretreated with 50 μM MG132, and incubated for 1 hour with [35S] methionine and 
cysteine. p53 and HSP90 proteins were immunoprecipitated from labeled cells, and analyzed by 
autoradiography after SDS-PAGE. Analysis of whole-cell extracts (WCE) showed comparable 
incorporation of [
35
S] methionine into dox-treated and untreated cells (bottom panel). B) Analysis of 
p53 mRNA distribution on polysomal fractions in HCT116shGTPBP4 cells treated as in fig. 11. 
Absorbance profile of RNA separated by velocity sedimentation through sucrose gradient. The position 
of the 40S, 60S, 80S, and polysomal fractions are indicated. C) Western blot analysis confirmed 
GTPBP4 depletion and p53 accumulation. Hsp90 protein has been analyzed as loading control. D) 
GAPDH and p53 mRNA distribution in sub- and polysomal fractions from untreated (blue line) or dox 
treated (red dashed) cells. In each fraction, mRNA expression levels measured by RT-qPCR were 
normalized on the total volume of the fraction. 
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Figure 13. GTPBP4 depletion promotes p53 stabilization in HCT116 cells.  
A)  Quantification is shown of the ratio of p53 to HSP90 (measured by densitometry on Western blots) 
in HCT116shGTPBP4 cells treated for 48 hours with Doxycycline (red dashed) or left untreated (blue 
line). 50 μM Cycloheximide (CHX) was added for the indicated times. Data are means ± SD for three 
independent experiments. B) Representative Western blot used for the analysis of p53 half-life. The gel 
was loaded with a reduced volume of Dox-treated lysates to obtain a comparable p53 signal.  
 
 
 
 
Impact of GTPBP4 depletion in ribosome biogenesis, and correlation with p53 
accumulation 
GTPBP4 is an essential factor in ribosome biogenesis (Jensen et al., 2003). The 
observation that GTPBP4 depletion can promote p53 stabilization and affects 
polysome profile, lead us to analyze the impact of GTPBP4 knockdown on ribosome 
biogenesis - and its correlation with p53 accumulation. 
To measure the impact of GTPBP4 depletion on processing of ribosomal RNA 
(rRNA) we first determined the kinetic of ribosomal processing in uninduced 
HCT116shGTPBP4 cells.  
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Cells were metabolically labeled with [
32
P] orthophosphate following the protocol 
illustrated in fig. 14B, and labeled total RNA was separated by gel electrophoresis and 
visualized by autoradiography. A schematic representation of rRNA processing is 
given in fig. 14A: primary 47S rRNA transcript is first processed into intermediate 
products and finally into the mature 18S, 5.8S, and 28S rRNAs.  
The kinetics of rRNA processing in HCT116shGTPBP4 cells are shown in fig. 14C 
(right panel): after 3 hours of chase, the 47S rRNA precursor is processed into the 28S 
and 18S forms. Hence, since GTPBP4 is involved in the processing of 60S ribosomal 
subunits (Jensen et al., 2003), we performed the next experiments using this time-
frame. 
HCT116shC and HCT116shGTPBP4 cells were treated with or without doxycycline 
for 24 and 48 hours, and then metabolically labeled with [
32
P] orthophosphate as 
summarized in fig. 15A. Total RNA was extracted, separated by gel electrophoresis 
and visualized by autoradiography. In parallel, cells were also collected for western 
blot analysis of GTPBP4 and p53 levels. 
In line with data obtained by others with GTPBP4/Nog1 mutants (Lapik et al., 2007), 
we observed that GTPBP4 depletion has a strong impact on ribosome biogenesis. A 
reduction in newly synthesized 28S rRNA is an early event following GTPBP4 
knockdown, since 28S rRNA production is almost abolished after 24 hours of 
doxycycline treatment. Altered 28S rRNA processing is specifically associated with 
reduced GTPBP4 levels, since no effects are observed in control cells (fig. 15B). 
Interestingly, western blot analysis indicates that p53 accumulation is a later event, 
subsequent to the defect in 28S rRNA synthesis triggered by GTPBP4 depletion (fig. 
15C). 
Collectively, these results demonstrate that alteration in ribosome biogenesis is an 
early event induced by GTPBP4 depletion, and suggest that the subsequent p53 
stabilization might be functionally linked to such condition. 
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Figure 14. Analysis of rRNA processing in HCT116 cells.  
A) Schematic representation of rRNA processing in mammalian cells. ETS, external transcribed 
spacer; ITS, internal transcribed spacer (adapted from Burger, 2010). B) Schematic representation of 
metabolic labeling experiment. Cells were cultured with complete medium, phosphate-depleted, and 
labeled with [
32
P]orthophosphate for 1 hour (pulse) before addition of excess complete medium with 
unlabeled phosphate (chase). Total RNA was isolated at the indicated times. C) Kinetics of rRNA 
processing in HCT116shGTPBP4 cells. Cells were labeled with 
32
P-orthophosphate for 1 h and chased 
with “cold” medium for the indicated time. RNA was extracted, and separated on denaturing agarose 
gel. Labeled RNA was visualized by autoradiography (right panel). Ethidium bromide staining of the 
gel confirmed equal loading of RNA (left panel). 
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Figure 15. GTPBP4 depletion affects ribosome biogenesis, correlating with p53 accumulation. 
A-B) GTPBP4 depletion affects rRNA processing. HCT116shC or HCT116shGTPBP4 cells were 
treated for 24 hours and 48 hours with Doxycycline or left untreated. Cells were labeled with 32P-
orthophosphate for 1 hour and chased with cold medium for 3 hours. Total RNA was extracted, 
separated on denaturing agarose gel and labeled RNA was visualized by autoradiography (top panels). 
Ethidium bromide staining of the gel confirmed equal loading of RNA (bottom panels). C) Expression 
levels of GTPBP4 and p53 were analyzed in the same cells by western blot. Actin was detected as 
loading control. 
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The RPs-Mdm2-p53 stress response pathway promotes p53 stabilization in 
GTPBP4 depleted cells  
Perturbations in any step of ribosome biogenesis have been demonstrated to induce a 
stress response leading to p53 activation and cell cycle arrest (Deisenroth and Zhang, 
2010). The mechanism of p53 activation relies on the cooperative binding of 
ribosomal proteins (RPs) RPL5 and RPL11 to Mdm2, and this leads to Mdm2 
inactivation and consequently p53 activation and cell cycle arrest (Zhou et al., 2012). 
This ribosome biogenesis surveillance mechanism has been defined the “RPs-Mdm2-
p53 stress response pathway” (Deisenroth and Zhang, 2010). 
We observed that GTPBP4 depletion affects ribosome biogenesis prior to p53 
accumulation, thus we asked whether the “RPs-Mdm2-p53 stress response pathway” 
could be responsible for p53 stabilization. 
To address this question we used RNAi to downregulate the ribosomal protein 
RPL11, a key mediator of the RPs-Mdm2-p53 axis. As shown in fig. 16A, RPL11 
knockdown is sufficient to prevent p53 accumulation induced by GTPBP4 depletion, 
thus suggesting that p53 accumulation upon GTPBP4 silencing requires Ribosomal 
Protein L11. 
Since the activation of p53 is mediated by the interaction of RPL11 with Mdm2, we 
asked whether GTPBP4 depletion would increase formation of such complex. 
Endogenous Mdm2 was immunoprecipitated and bound RPL11 was visualized by 
western blot upon doxycycline treatment of HCT116shGTPBP4 cells. We observed 
that GTPBP4 depletion promotes RPL11 binding to Mdm2 (fig. 16B), thus further 
suggesting that p53 stabilization upon GTPBP4 knockdown might derive from RP- 
mediated inhibition of Mdm2 functions. 
To further clarify if GTPBP4 depletion promotes p53 accumulation through the RPs-
Mdm2-p53 axis, we treated GTPBP4 depleted cells with two chemotherapeutic drugs, 
Actinomycin D (ActD) and 5-Fluorouracil (5-FU), at conditions known to specifically 
trigger ribosomal stress and activate the RPs-Mdm2-p53 axis (Bhat et al., 2004; Sun 
et al., 2007). As shown in fig. 16C, GTPBP4 depletion does not promote a further 
increase in p53 levels upon drug treatment, indicating that the same pathway might 
control p53 accumulation upon GTPBP4 knockdown and drug-induced ribosomal 
stress. 
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Collectively, these results strongly suggest that GTPBP4 depletion, by affecting 
ribosome biogenesis, activates the “RPs-Mdm2-p53 stress response pathway”, leading 
to p53 stabilization and cell cycle arrest. 
 
 
 
Figure 16. The RPs-Mdm2-p53 stress response pathway promotes p53 stabilization in GTPBP4 
depleted cells.  
A) RPL11 is required for p53 accumulation induced by GTPBP4 depletion. HCT116shGTPBP4 cells 
were silenced with control siRNA (siCtrl) or siRNA targeting RPL11 (siRPL11) for 16 hours. Cells 
were then collected and plated in presence or absence of Doxycycline for additional 48 hours. Western 
blot analysis shows p53 levels. Blot for GTPBP4 and RPL11 confirms depletion of the endogenous 
proteins. HSP90 was blotted as loading control. B) GTPBP4 depletion promotes the interaction of 
Mdm2 with RPL11. HCT116shGTPBP4 cells were treated with doxycycline for 48 hours or left 
untreated and subjected to immunoprecipitation with anti-MDM2 (SMP14) antibody. 
Immunoprecipitated proteins (IP, right panel) and 5% of total lysates (input, left panel) were subjected 
to western blot analysis with the indicated antibodies. C) GTPBP4 depletion does not cooperate with 
nucleolar stress to increase p53 levels. Doxycycline treated or untreated cells were exposed to 5nM 
Actinomycin D (ActD) and 50μM 5-Fluorouracil (5-FU) for 8 hours. Western blot for p53 and 
GTPBP4 is shown. HSP90 was blotted as loading control.  
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Impact of different ribosomal stresses on p53 stabilization 
Currently, at least 3 types of nucleolar stress that can be experimentally induced in 
cells, have been reported to activate p53. 1) Inhibition of RNA Pol I, for example by 
Actinomycin D treatment; 2) depletion of selected ribosomal proteins, for example 
RPL30 and RPS6; 3) depletion or mutation of accessory factors necessary for 
ribosome biogenesis, such as Bop1 or Pes1. All these conditions have been reported 
to affect ribosome biogenesis and promote p53 accumulation. For the first two types 
of stress, it has been convincingly proven that p53 accumulation depends on the 
activation of the RPs-Mdm2-p53 axis (Deisenroth and Zhang, 2011; Zhou et al., 
2012); for the third type of stress, several papers reported p53 accumulation after 
depletion of Bop1, Pes1, or other cofactors, but none of the studies formally 
demonstrated p53 stabilization, or proved the involvement of the aforementioned 
regulatory axis in governing p53 levels.  
We demonstrated that the depletion of ribosomal processing factor GTPBP4 promotes 
a two-fold increase in p53 half-life and that such stabilization requires the activation 
of the RPs-Mdm2 axis. 
Intriguingly, published data indicate that various ribosomal stressors promoting the 
activation of the RPs-Mdm2 axis have a much greater impact on p53 stability than 
what we observed with GTPBP4 depletion. Hence we asked whether the extent of p53 
stabilization upon different types of ribosomal stress could be intrinsically dependent 
on the nature of the stress itself.  
To answer this question, we analyzed the effects on ribosome biogenesis and p53 
stability of the depletion of two proteins that induce different ribosomal stress 
features: RPL30, and Bop1. RPL30 depletion affects nucleolar structure and induces a 
consistent increase in p53 stability via the RPs-Mdm2-p53 axis (Sun et al., 2010). In 
contrast, Bop1 is a ribosome associated factor involved in the late phases of 
maturation of the 60S ribosome subunit, much like GTPBP4  (Strezoska et al., 2002). 
HCT116 cells were transfected with siRNAs targeting Bop1 or RPL30, and rRNA 
processing was analyzed by 
32
P-orthophosphate labeling. As shown in fig. 17A, both 
Bop1 and RPL30 depletion strongly affects 28S rRNA biogenesis. Interestingly, the 
depletion of either protein seems to affect rRNA processing after the cleavage of pre-
18S rRNA, since newly synthesized 18S rRNA is not affected. Western blot analyses 
confirmed that RPL30 or Bop1 depletion promotes p53 accumulation (fig. 17B). 
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After verifying the role of RPL30 and Bop1 in ribosome biogenesis, we analyzed the 
impact of RPL30 and Bop1 depletion on p53 stability through a cycloheximide 
experiment. Efficient knockdown of those proteins was controlled by RTqPCR as 
shown in the top panel of fig. 17C. Although the data are preliminary, depletion of 
either protein increases p53 half-life (fig. 17C, bottom panel), thus suggesting that in 
both cases altered ribosome biogenesis induces a checkpoint leading to p53 
stabilization. 
Performing a densitometric analysis of the bands, the extent of p53 stabilization upon 
GTPBP4, RPL30, and Bop1 depletion was quantified. As shown in fig. 17D, in 
RPL30 depleted cells p53 half-life is strongly increased. In GTPBP4 and Bop1 
depleted cells, p53 half-life is also increased, but is sensibly shorter that in RPL30-
depleted cells. 
Notably, the increase in p53 half-life is remarkably similar in cells depleted of 
GTPBP4 or Bop1. 
 
Although not definitive, these data suggest that the intensity of p53 stabilization might 
be different depending on the type of ribosomal stress. Defective ribosome processing 
in the absence of nucleolar disruption, induced in our case by GTPBP4 or Bop1 
depletion, seems to intersect the p53 pathway with a lower impact than other 
ribosomal stressor, such as the depletion of ribosomal proteins, that induce nucleolar 
structure alterations. Nonetheless, at least for GTPBP4 depletion, I demonstrated that 
p53 accumulation requires the activation of the “RPs-Mdm2-p53 stress response 
pathway” which is also activated in response to nucleolar disruption. 
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Figure 17. Impact of different ribosomal stress conditions on p53 stabilization. 
A) Bop1 or RPL30 depletion affects 28S ribosome processing. HCT116 cells were treated for 48 hours 
with control siRNA (siCtrl), siRNA targeting RPL30, or two siRNAs targeting Bop1 (in the 3‟-UTR 
and in the coding sequence, CDS). Cells were pulse-labeled (right panel) and rRNA processing was 
visualized as in fig. 15A. Ethidium bromide staining of the gel shows loading of RNA (left panel). B) 
Bop1 or RPL30 depletion triggers p53 accumulation. HCT116 cells were treated as in A, and analyzed 
by western blot with anti-p53 antibody. HSP90 was used as loading control. C-D) RPL30 or Bop1 
depletion induces p53 stabilization. HCT116 cells were treated as in A (siRNA BOP1 3‟-UTR was 
used). C) The efficiency of RPL30 and BOP1 depletion was measured by RT-qPCR (upper panel). 
Data were normalized to GAPDH, and compared to expression levels of untreated cells. Half-life of 
p53 was evaluated by immunoblotting after CHX treatment as described in fig. 13A. The gel was 
loaded with reduced amount of lysate from siRNA-treated cells to obtain a comparable p53 signal at 
the 0h point. D) Comparison of p53 half-life upon different ribosomal stresses. Quantification is shown 
of the ratio of p53 to HSP90 (measured by densitometry on Western blots). Data for RPL30 and Bop1 
silencing are from the experiment in panel C; data for GTPBP4 silencing refer to the inducible 
HCT116shGTPBP4 cell line, and are extracted from fig. 13. 
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PART 1: DISCUSSION 
 
Our group identified the protein GTPBP4 as a novel, evolutionary conserved 
interactor of wild-type p53 (Lunardi et al., 2010).  The nucleolar protein GTPBP4 is 
an essential processing factor required for biogenesis of 60S ribosomal subunit 
(Jensen et al., 2003), indeed, yeast cells depleted of GTPBP4 or harboring 
temperature sensitive alleles of the gene display defects in pre-rRNA processing and 
in the release of nascent pre-60S subunits from the nucleolus (Kallstrom et al., 2003; 
Saveanu et al., 2003). Our primary interest in GTPBP4 derived from the observation 
that its depletion by siRNA induced accumulation and activation of p53, without 
apparently affecting nucleolar functions. Indeed we observed that GTPBP4 depletion 
did not alter nucleolar structure, and  most importantly, p53 accumulation was 
apparently not due to increased protein half-life. Collectively these preliminary data, 
prompted us to initially exclude the ribosomal surveillance pathway as the mechanism 
promoting p53 accumulation upon GTPBP4 depletion (Lunardi et al., 2010) and 
incited us to explore a direct involvement of GTPBP4 in controlling p53 translation. 
To dissect this potentially novel regulatory axis, we generated a stable cell line 
engineered for inducible GTPBP4 knockdown. In this model system, 
35
S methionine 
labeling experiments and analysis of RNA loading on polysomes, revealed no 
evidences of increased p53 translation in cells depleted of GTPBP4. Conversely, 
meticulous cycloheximide experiments, revealed that GTPBP4 depletion in fact 
increases p53 stability.  
We then demonstrated that the mechanism responsible for such accumulation relies 
on the “RPs-Mdm2-p53 stress response pathway”, probably activated by a defect in 
rRNA processing triggered by GTPBP4 depletion (fig. 15).   
In recent years, the depletion of many ribosomal proteins and accessory factors 
involved at different levels in ribosome biogenesis has been reported to activate the 
“RPs-Mdm2-p53 stress response pathway (Deisenroth and Zhang, 2011). 
Interestingly, depletion of accessory factors involved in late ribosomal processing, 
such as Bop1, Pes1, or others, has been reported to trigger p53 accumulation, but none 
of the studies rigorously demonstrated the mechanism involved. Our data, for the first 
time demonstrate that p53 accumulation upon impairment of late ribosomal 
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processing - triggered in our case by GTPBP4 depletion – also requires the activation 
of the RPs-Mdm2 axis.  
Remarkably, the depletion of Bop1, a ribosomal associated factor, promotes p53 
stability to a similar extent as GTPBP4 knockdown, while the depletion of RPL30 has 
a significantly greater impact on p53 half-life. Interestingly, when we analyzed how 
the depletion of these proteins affects rRNA processing, we found no relevant 
differences (fig. 17A). These preliminary observations raise the intriguing hypothesis 
that a distinct degree of p53 stabilization can be triggered by the RPs-Mdm2 axis, 
depending on the specific type of nucleolar stress. Indeed, in other conditions of 
nucleolar stress, all triggering the activation of the RPs-Mdm2-p53 axis, p53 half-life 
is increased to a greater extent than upon GTPBP4 or Bop1 depletion (Sun et al., 
2007; Sun et al., 2010; Yu et al., 2011). One common instance is that a stronger p53 
stabilization is probably observed upon treatments that provoke nucleolar disruption 
(i.e. ActD, RpL30 knockdown), while in GTPBP4 depleted cells the nucleolar 
structure is preserved. 
 
It should be noted that we had identified GTPBP4 as a novel p53 interacting protein, 
but the mechanism of p53 accumulation upon GTPBP4 depletion seems to be 
independent from their physical interaction. Thus, the potential functional 
significance of the interaction between p53 and GTPBP4 is still to be elucidated. 
One intriguing hypothesis is that p53 itself, through GTPBP4 interaction, might 
regulate the late steps of rRNA processing and the maturation of 60S ribosomes, in 
turn influencing the translational apparatus of the cell. Interestingly, p53 has been 
already demonstrated to control other steps of ribosome biogenesis, for instance by 
regulating RNA pol I and pol III activity (Krastev et al., 2011; Zhai and Comai, 
2000). An inhibitory action of p53 on 60S ribosome maturation could be part of a 
tumor-suppressive response to activation of proto-oncogenes that promote ribosomal 
synthesis such as Ras and Myc. 
Being independent of its transcriptional functions, interaction with cofactors involved 
in ribosome maturation could be a preferential activity of N-terminal truncated p53 
isoforms (i.e. DN p53). 
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The dependency of cancer cells on increased ribosome biogenesis has been recently 
exploited to identify new drugs that specifically target this biological process. In fact, 
a specific inhibitor of RNA pol I has been recently developed and is now in clinical 
trial (Drygin et al., 2011). Accessory proteins involved in ribosome biogenesis, 
specifically deregulated in tumors, could expand the list of potential targets for this 
type of therapy. 
High expression levels of GTPBP4 correlate with reduced survival in breast cancer 
bearing wild-type p53 (Lunardi et al., 2010). Interestingly, we observed that the 
expression of various other proteins involved in late ribosomal processing inversely 
correlates with survival in breast cancer tumors (fig. 18). It may be interesting to 
assess the addiction of tumor cells on the elevated expression of these ribosomal 
processing factors, and eventually find drugs that - by specifically targeting these 
cofactors – would activate the RPs-Mdm2-p53 axis, increasing p53 stability 
preferentially in tumor cells. Elevated p53 levels could then be exploited to sensitize 
cancer cells to conventional chemotherapy.  
 
 
 
Figure 18.  Cumulative survival (Kaplan–Meier) analysis showing that higher expression of ribosomal 
processing factors GTPBP4, Bop1, Wdr12, and Pes1, significantly correlates with reduced survival in a 
large dataset (circa 1400 samples) of breast cancer patients with 12 years clinical follow-up.
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PART 2: Effect of altered ribosome biogenesis on mutant p53 
stability 
 
Deregulated ribosome biogenesis triggers a checkpoint leading to the activation of 
wild type p53 tumor suppressor activity (Macias et al., 2010). However, the p53 
pathway is impaired in most human cancers, so the above checkpoint is frequently 
non-functional in tumor cells. 
In fact a large proportion of human tumors carry p53 mutations, and most of these are 
missense mutations that result in production of a mutant protein that not only loses 
tumor-suppressing activities, but also acquires new pro-oncogenic activities, defined 
as gain of function. Specifically, mutant p53 enhances proliferation and survival of 
cancer cells, and increases tumorigenesis in vivo when compared with p53-null cells 
or mice (Brosh and Rotter, 2009).  
In opposition to the wild type counterpart, which is highly unstable, mutant p53 is 
often found at high levels in tumors (Bartek et al., 1991), and high mutant p53 protein 
levels are thought to be responsible for most of its oncogenic functions (Muller and 
Vousden, 2013).  
Mice models and studies with cultured cells highlighted the prominent role of Mdm2 
in the regulation of mutant p53 stability (Li et al., 2011; Suh et al., 2011; Terzian et 
al., 2008), thus suggesting the hypothesis that cellular stimuli known to activate the 
tumor suppressive activity of wild type p53, could in turn promote the oncogenic 
functions of mutant p53. 
Since ribosome biogenesis is almost invariably deregulated in tumors, we 
hypothesized that one of the regulatory mechanisms that contribute to mutant p53 
stability might be represented by the inhibition of Mdm2 functions through the 
binding of unbalanced ribosomal proteins. 
We therefore decided to analyze whether mutant p53 could be indeed stabilized by the 
“RPs-Mdm2-p53 stress response pathway”. 
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PART 2: RESULTS 
 
Altered ribosome biogenesis promotes mutant p53 stability 
Increased ribosome biogenesis is frequently observed in human cancers, mainly as a 
result of the amplified biosynthetic demand linked to uncontrolled cell proliferation. 
In cells with wtp53, a deregulated ribosome processing activates a cellular 
checkpoint, known as the “RPs-Mdm2-p53 stress response pathway” that promotes 
tumor suppression wild-type p53 (Deisenroth and Zhang, 2010). 
Since mutant p53 retains some of the regulatory mechanisms of the wild type 
counterpart (Terzian et al., 2008), it is conceivable that signaling pathways promoting 
the activation of wt p53, could instead increase stability of mutant p53, thereby 
promoting its oncogenic potential. Among these double edged processes, we reasoned 
that altered ribosome biogenesis might contribute to increased mutant p53 expression 
levels.  
More specifically, we  asked whether the “RPs-Mdm2-p53 stress response pathway”, 
could promote mut-p53 protein stability. After a survey of available lines, we chose 
the ovarian carcinoma Ovcar3 cell line, bearing the p53 R248Q mutation. The choice 
of this cell line is due to the relatively low levels of endogenous mutant p53, allowing 
studies aimed to detect a further increase in mutant p53 protein levels. 
We treated cells with two chemotherapeutic drugs, Actinomycin D and 5-florouracil, 
at concentrations and timing known to specifically affect ribosome biogenesis (Perry 
and Kelley, 1968, 1970; Sobell et al., 1971; Sun et al., 2007). As shown in the left 
panel of fig.19A, drug treatments promote mutant p53 accumulation, indicating that 
mutp53 indeed responds to nucleolar stress. 
To confirm this observation under conditions in which the DNA-damage response is 
certainly not involved, we induced nucleolar stress by siRNA mediated depletion of 
ribosomal protein RPL30, and ribosomal processing factors GTPBP4 and Bop1. As 
shown in the right panel of fig.19A, also in these conditions mutant p53 levels are 
increased, thus confirming that altered ribosome biogenesis can promote mut-p53 
accumulation.  
Since ribosomal stress promotes the inhibition of Mdm2 E3 ubiquitin ligase activity 
(Deisenroth and Zhang, 2010), we asked whether increased mut p53 levels are the  
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Figure 19. Altered ribosome biogenesis increases stability of mutant p53. 
A) Various ribosomal stress conditions induce mutant p53 accumulation. Ovcar-3 cells were exposed 
to 5nM ActD or 50μM 5-FUfor 8 hours (left panel), or were treated for 48 hours with control siRNA or 
siRNA targeting GTPBP4, RPL30, or Bop1 (right panel). Western blots of p53 are shown. HSP90 was 
used as loading control. B) Nucleolar stress increases mutant p53 half-life. Ovcar-3 cells were treated 
with Actinomycin D as in panel A, and 50 μM Cycloheximide (CHX) was added for the indicated 
times. Analysis of p53 half-life is shown by western blot (bottom left panel) and quantification by 
densitometry (right graph).The gel in the figure was loaded to obtain a comparable p53 signal at 0h 
time point; accumulation of mutant p53 under these conditions was confirmed by an ad hoc western 
blot using identical quantities of lysate (top left panel). C) RPL30 or GTPBP4 knockdown increases 
mutant p53 stabilization. Ovcar-3 cells were treated with siRNA as described in panel A. Analysis of 
mutant p53 half-life after CHX treatment was performed as described for panel B. 
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result of increased mutant p53 half-life. To this aim, we performed cycloheximide 
experiments upon Actinomycin D treatment, and RPL30 or GTPBP4 silencing. 
As shown in fig. 19B, Actinomycin D treatment strongly promotes mutant p53 
stabilization. Similarly, GTPBP4 and RPL30 knockdown also increase mutant p53 
half-life, although with lower efficiency (fig. 19C).  
These results indicate that ribosomal stress can stabilize and activate mutant p53, as 
well as wild type p53.  
 
The RPs-Mdm2 axis promotes mutant p53 stabilization upon altered ribosome 
biogenesis 
Since we observed that different ribosomal stressors promote mutant p53 
stabilization, we asked whether the RPs-Mdm2 axis is responsible of this effect. 
Critical mediators of this axis are RPL5 and RPL11, that cooperatively bind Mdm2 
and inhibit its functions. 
We therefore treated Ovcar3 cells with Actinomycin D (ActD) and 5-fluorouracil (5-
FU), and analyzed Mdm2-bound RPL11 by co-immunoprecipitation. We observed 
that ribosomal stress induced by ActD and 5FU treatments promotes RPL11 binding 
to Mdm2 (fig. 20A), thus suggesting that mutant p53 stabilization is induced by RPs-
mediated Mdm2 inhibition. 
To further confirm the role of RPs in mutant p53 stabilization upon ribosomal stress, 
we silenced RPL11, and analyzed mutant p53 accumulation upon ActD and 5FU 
treatment. As shown in fig 20B, RPL11 silencing prevents p53 accumulation upon 
ribosomal stress, thus confirming the role of the RPs-Mdm2 axis in promoting mutant 
p53 stabilization. 
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Figure 20. The RPs-Mdm2 axis promotes mutant p53 stabilization upon altered ribosome 
biogenesis. 
A) ActD and 5-fluorouracil treatments promote RPL11 binding to Mdm2. Ovcar-3 cells were treated 
with ActD and 5-FU as in fig. 19A, and subjected to immunoprecipitation with anti-MDM2 (SMP14) 
antibody. Immunoprecipitated proteins (IP, top panel) and 5% of each total cell extract (input, bottom 
panel) were subjected to western blot analysis with the indicated antibodies. B) RPL11 knockdown 
prevents p53 accumulation induced by nucleolar stress. Ovcar-3 cells were silenced with control 
siRNA (siCtrl) or siRNA targeting RPL11 (siRPL11) for 48 hours, and then treated with ActD and 5-
FU for 8 hours. Levels of mutant p53 were analyzed by western blot; HSP90 was detected as loading 
control. 
 
 
Potential biological impact of mutp53 accumulation by ribosomal stress in 
cancer cells 
An increase in stabilization and accumulation of mutp53 may amplify its gain-of-
function properties (Muller et al., 2009), eventually augmenting its oncogenic 
potential. This might have a relevant impact in the use of ribosomal-damaging drugs 
for chemotherapy of cancers bearing p53 mutations. 
To examine the potential significance of increasing mutant p53 levels by ribosomal 
stress, we analyzed the motility of cancer cells by performing an in vitro migration 
assay. Ovcar3 cells were transfected with control siRNA or p53 siRNA for 48 hours 
and then treated for additional 8 hours with ActD or left untreated. Cells were then 
collected and used for transwell migration assays in the absence of drug. Treatment 
with ActD augmented mutant p53 levels (fig. 21, right panel) and promoted a 
significant increase in cell migration (fig. 21, left panel), confirming that 
input
IP: Mdm2
NT ActD 5-FU
RPL11
p53
HSP90
RPL11
Mdm2
p53
HSP90
NT ActD 5-FU
siControl siRPL11
NT ActD 5-FU
A
B
 PART 2 
 
64 
 
accumulation of mutant p53 may have biologically relevant consequences. 
Importantly, the observed increase in cell migration is dependent on mutant p53, since 
p53 knockdown abolishes this phenotype. 
Collectively, these results indicate that altered ribosome biogenesis can increase 
stability of mutant p53 via the same pathway that stabilizes wild type p53. Moreover, 
such increased mutp53 levels can be biologically relevant, since they promote a 
classical mutant p53 phenotype such as cell migration. 
 
 
 
 
Figure 21. Mutant p53 stabilization by nucleolar stress can promote cell migration. 
ActD treatment increases motility of cancer cells through a mechanism that requires mutp53. Ovcar-3 
cells were transfected with control siRNA or p53 siRNA for 48 hours, and treated for additional 8 
hours with ActD or DMSO. Cells were then collected and used for transwell migration assays in the 
absence of drug. Error bars indicate standard deviation (n=3, *p<0.05 one-tailed t-test). p53 
accumulation upon ActD treatment and efficiency of p53 silencing were controlled by western blot of 
the same cells (right panel). 
 
 
Development of a tool for studying the RPs-Mdm2-mutp53 axis in tumorigenesis 
Mutp53 can be stabilized in tumors by various mechanisms; here we have shown that 
widely used chemotherapeutic drugs such as 5-FU can induce mutp53 stabilization 
through ribosomal stress. To experimentally evaluate the specific impact of 
deregulated ribosome biogenesis in the oncogenic functions of mutant p53, however, 
we need to specifically inhibit the RPs-Mdm2 axis, thus uncoupling ribosomal stress 
from Mdm2 functions, without affecting other pathways. 
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Preventing mutant p53 accumulation by altered ribosome biogenesis can be achieved 
by depleting those ribosomal proteins responsible for Mdm2 inhibition. We 
biochemically demonstrated in fig. 20B that RPL11 is an essential mediator of the 
RPs-Mdm2 axis, since its knockdown completely abolishes mut-p53 accumulation 
upon ribosomal stress. However, RPL11 is a constitutive ribosomal protein, and its 
depletion could in the long time globally affect cell homeostasis, regardless of mutant 
p53. 
Indeed, experiments with RPL11 knock-down should be done over short time frames, 
and in any case the potential impact on the ribosome pool must be considered when 
analyzing the results. 
We took advantage of previous studies that determined the crucial importance of 
RPL5 and RPL11 for this checkpoint, and mapped the region of Mdm2 where these 
proteins bind (Zhang et al., 2003). 
We then reasoned that to prevent mutant p53 accumulation by the RPs-Mdm2 axis, it 
might be sufficient to sequester the nuclear pool of free RPL11 that is presumably 
increased upon ribosomal stress. So, overexpression of a polypeptide corresponding to 
the specific region of Mdm2 that binds RpL11 would prevent its interaction with 
endogenous full-length Mdm2. 
Thus we cloned in an HA-tag expression vector the Mdm2 region between aa 284 and 
374, that has been reported to specifically interact with RPL11. Moreover, since 
RPL11 has been reported to bind and cooperate with RPL5 in promoting Mdm2 
inhibition upon ribosomal stress (Bursac et al., 2012; Donati et al., 2013), we also 
cloned a larger Mdm2 region, from aa 216 to 374, that binds both RPL5 and RPL11 
(Zhang et al., 2003) (fig. 22A).  
We first compared the ability of these two peptides to bind RPL11. We cotransfected 
myc-tagged RPL11 alone or with HA-tagged peptides, and analyzed bound RPL11 
co-immunoprecipitated with the peptide. As shown in fig. 22B, the 216-274 Mdm2 
fragment binds more efficiently to my-tagged RPL11, than the 278-374 peptide. 
Moreover, we could easily observe interaction between endogenous RPL11 and HA-
tagged 216-374 peptide (fig. 22C).  
It is widely assumed that ribosomal stress causes an increase in free RPL11. In order 
to verify the ability of the Hdm2(216-374) peptide to detect such increased free 
RPL11, we treated Hdm2(216-374)-transfected cells with Actinomycin D, and 
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analyzed RPL11 binding to the peptide by HA-tag immunoprecipitation. As shown in 
fig. 22D ribosomal stress enhances RPL11 binding to the peptide. Interestingly, it 
appears that the Hdm2-peptide may be used as an efficient probe to detect free RPL11 
in cells. 
In conclusion, the use of this peptide, if validated, could be an alternative way to 
study the role of RP-Mdm2 axis, in promoting the oncogenic functions of mutant p53 
upon deregulated ribosome biogenesis. 
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Figure 22. Development of a Mdm2-derived expression construct as a tool for studying the RPs-
Mdm2-mutp53 axis in tumorigenesis. 
A) Schematic representation of the Hdm2 protein and the two peptides used in this study (adapted from 
Zhang et al., 2003). B) The peptide Hdm2(216-374) binds more efficiently than Hdm2(284-374) to 
overexpressed RPL11. H1299 cells were transfected with the indicated plasmids for 48 hours and 
subjected to immunoprecipitation with anti-HA (12CA5) antibody. Immunoprecipitated proteins (IP) 
and 5% of each total cell extract (input) were subjected to western blot analysis with the indicated 
antibodies. C) The Hdm2(216-374) construct binds endogenous RPL11. H1299 cells were transfected 
with a plasmid encoding HA-Hdm2(216-374) or empty vector for 48 hours, and subjected to 
immunoprecipitation and immunoblot as in B. D) Actinomycin D treatment enhances RPL11 
binding to the Hdm2(216-374) peptide. U2OS cells were transfected with plasmid encoding for HA-
Hdm2(216-374) or an empty vector for 24 hours. Cells were then collected and splitted into two plates. 
24 hours later cells were treated with 5nM Actinomycin D or DMSO for additional 8 hours, and 
subjected to immunoprecipitation with anti-HA (12CA5) antibody. Immunoprecipitated proteins (IP) 
and 5% of total cell extracts (input) were subjected to western blot analysis with the indicated 
antibodies. 
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PART 2: DISCUSSION 
 
Increased mutant p53 levels are a common feature of high grade tumors (Bartek et al., 
1991). Many evidences suggest that high levels of mutant p53 protein are responsible 
for most of its oncogenic functions (Muller and Vousden, 2013); indeed, its 
precocious stabilization in knock-in mice is associated with enhanced aggressiveness 
(Suh et al., 2011; Terzian et al., 2008). However, in contrast to the plethora of 
information available for wild type p53, the mechanisms dictating mutant p53 
stability are much less characterized (Brosh and Rotter, 2009). 
We found that the “RPs-Mdm2-p53 stress response pathway” can promote mutant 
p53 stabilization upon impaired ribosome biogenesis in cancer cells. Importantly, we 
observed that increased mutp53 levels may have a relevant functional impact, since 
they foster a mutant p53-dependent phenotype such as cell migration. 
These results raise two interesting considerations. 
The first concerns the mechanism of mutp53 stabilization in tumor cells. In fact, since 
altered ribosome biogenesis is a common feature to cancer cells, it is possible that a 
“constitutive ribosomal stress” generated by oncogenic transformation might be 
responsible for increased mutant p53 levels by activating the RPs-Mdm2 axis. To test 
this hypothesis, it would be necessary to interfere with the Rp-Mdm2-p53 axis 
without affecting the protein synthesis apparatus. This could be elegantly approached 
by generating double transgenic mice with the knock-in of mutant p53 in the context 
of the Mdm2
C305F
 point mutation (Macias et al., 2010); this mutation uncouples the 
interaction between free ribosomal proteins and Mdm2, and would allow the study of 
mutp53 stability (and tumorigenicity) in the absence of a functional Rp-Mdm2-p53 
axis. Less elegant, but more accessible, is the generation of cell lines with stable 
expression of the Hdm2(216-374) peptide described in Fig. 22. High levels of the 
peptide might in fact reduce the interaction between free ribosomal proteins and 
Mdm2, thus interfering with the Rp-Mdm2-p53 axis. This is currently in progress. 
 
The second consideration regards the possible implications in the choice of 
chemotherapy. In fact, many commonly used chemotherapeutic drugs have been 
reported to impinge on ribosome biogenesis (Burger et al., 2010), and it is possible 
that activation of the nucleolar stress response pathway could be detrimental in tumors 
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that bear TP53 missense mutation. In fact, we have shown that this pathway triggers 
mutant p53 stabilization, and increased mutp53 levels promote chemoresistance and 
metastasis (Muller et al., 2009) . Thus, the use of drugs such as 5-FU or ActD, that 
inhibit ribosome biogenesis at low concentrations, could be counterproductive in 
treating tumors that carry p53 mutations. Our data provide yet another evidence that 
the status of p53 should probably be taken into consideration when defining a 
chemotherapy regimen. 
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 CONCLUSIONS  
 
Ribosome biogenesis is a very complex process involving transcription as well as 
many post-transcriptional steps to produce functional ribosomes. 
Cells actively monitor the process of ribosome biogenesis, consequently activating 
cellular checkpoints when this process is deregulated (Boulon et al., 2010). The best 
understood of such checkpoints is the nucleolar stress pathway (also called the 
ribosomal surveillance pathway). The key event of this pathway is the modulation of 
the E3 ubiquitin ligase Mdm2 by a subset of RPs that, upon altered ribosome 
biogenesis, are released in the nucleoplasm (Zhang and Lu, 2009) where they bind 
Mdm2, inhibiting its ubiquitin ligase activity (Lee and Gu, 2010). 
Part of the work presented in this Thesis demonstrates that the RPs-Mdm2 axis is 
responsible for wild-type p53 stabilization upon depletion of the nucleolar protein 
GTPBP4. Specifically, we observed that GTPBP4 depletion affects 28S rRNA 
processing, and this correlates with p53 stabilization mediated by the inhibitory effect 
of RPL11 on Mdm2. 
In this Thesis we also report that the RPs-Mdm2 axis–normally responsible for the 
tumor suppressive functions of wild-type p53 upon deregulated ribosome biogenesis 
is also implicated in the regulation of mutant p53 stability, with potentially oncogenic 
consequences. 
Indeed, we observed that various nucleolar stress conditions can promote stabilization 
of wild-type p53 as well as mutant p53, very likely through the same molecular 
mechanism based on the inhibitory binding of RPL11 toMdm2. 
Collectively, these results support the notion that the process of ribosome biogenesis 
has an active role in tumorigenesis. We propose that upon deregulated ribosome 
biogenesis, or nucleolar stress, the TP53 status may be critical to drive the nucleolar 
surveillance pathway towards a tumor suppressive or oncogenic outcome. 
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MATERIALS AND METHODS 
 
Cell Culture, Transfections, Retroviral Transductions and treatments. HCT116, 
HCT116shC, HCT116shGTPBP4, 293T, U2OS cells were cultured in DMEM 
medium supplemented with 10% FCS (ECS0180L, Euroclone), and antibiotics 
(DE17-602E, Lonza). H1299 were cultured in RPMI medium supplemented with 10% 
FCS and antibiotics. OVCAR-3 were cultured in RPMI medium supplemented with 
20% FCS, insulin  (10μg/ml), and antibiotics. 
For siRNA transfections, cells were transfected with 40 nM siRNA oligonucleotides 
using Lipofectamine RNAiMax (Invitrogen), following manufacturer‟s instructions. 
siRNAs used in this work are listed in the following table: 
 
siRNA Sequence Purchase from/ Reference 
Control 
siRNA (SiQ) 
Unknown All star negative control 
(1027281,Qiagen) 
sip53 ORF GACUCCAGUGGUAAUCUAC Eurofins MWG 
siRPL30 AACTGGTGTCCATCACTACAG Eurofins MWG 
siBOP1 UTR UCGUGCUGAAGUCAACAGA Eurofins MWG 
siBOP1 CDS AUGGCAUGGUGUACAAUGA Eurofins MWG 
 
For DNA transfection, cells were transfected with Lipofectamine 2000 (Invitrogen), 
following manufacturer‟s instructions. 
For lentiviral production, manufactures procedures were followed (ViraPower
TM
 
Lentiviral Expression Systems, Invitrogen MAN0000273).   
 
Plasmids.  pLPC-HDM2 peptides were generated by clonig PCR products 
generated using specific primers with AccuPrime™ Taq DNA Polymerase High 
Fidelity (Invitrogen), following manufacturer‟s instructions. The pcDNA3-myc3-
RPL11 plasmid was purchased from Addgene (#19972). 
 
Western blot analysis and antibodies. Total cell extracts were prepared in RIPA 
buffer without SDS (150mM NaCl, 50mM Tris-HCl pH8, 1mM EDTA, 1% NP-40, 
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0,5% Na-deoxycholate) supplemented with 1 mM PMSF, 5 mM NaF, 1 mM Na3VO4, 
10μg/ml CLAP, 1μM TSA and 5μM nicotinamide. Protein concentration was 
determined with Bio-Rad Protein Assay Reagent (#500-0006, Bio-Rad). Lysates were 
resolved by SDS/PAGE and transferred to nitrocellulose (Millipore). Western blot 
analysis was performed according to standard procedures using the following primary 
antibodies: 
 
Target Antibody 
p53 (DO1) sc-126 (Santa Cruz) 
Actin #A9718 (Sigma) 
HSP90 sc-13119 (Santa Cruz) 
GTPBP4 13897-1-AP (protein  tech) 
RPL11 ab79352 (Abcam) 
Mdm2 2A10 home made preparation 
Mdm2 SMP14 (Santa Cruz) 
Myc-tag Cell Signaling #2272 
HA-tag 12CA5 home made preparation 
HA-tag Y-11 (sc-805 santa Cruz) 
 
FACS analysis. For FACS analysis, adherent and floating cells were harvested, 
permeabilized with 0.1% NP-40 in PBS containing RNase A (200 μg/ml) and then 
stained with 50 μg/ml Propidium Iodide (#P4865, Sigma). At least 20.000 cells were 
counted in each experiment, using a FACSCalibur flow cytometer (Becton-
Dickinson). Cell cycle analysis was performed with FlowJo software,  
(http://www.flowjo.com/). 
 
RNA extraction and RT-qPCR. Total RNA was extracted with QIAzol lysis reagent 
(Qiagen) following manufacturer‟s instructions. 1μg of total RNA was reverse-
transcribed with QuantiTect Reverse Transcription (Qiagen). The genes of interest 
were amplified with Fast SYBR® Green Master Mix (Applied Biosystems) following 
manufacturer‟s instructions. A CFX96 Touch™ Real-Time PCR System (Biorad) was 
used for qPCRs. List of primers used: 
 
 Materials and Methods 
 
73 
 
Target Sequence 
p53 Fw 5‟-CTCCTCTCCCCAGCCAAAGA-3‟ 
Rev 5‟-GGAACATCTCGAAGCGCTCA-3‟ 
GAPDH Fw 5'-CATGCCATCACTGCCACCC-3' 
Rev 5'-ACCTGGTCCTCAGTGTAGC-3' 
GTPBP4 Fw 5‟-CTGGAGGATAGGAACACC-3‟ 
Rev 5‟-TGGCTACAACTATGAGAG-3‟ 
RPL30 Fw 5‟-AGTGGGAAGTACGTCCTGGGGT-3‟ 
Rev 5‟-TCCGCATGCTGTGCCCAGTT-3‟ 
BOP1 Fw  5‟-AGCCCTTGATGACGAGGGCCA-3‟ 
Rev 5‟-GCCCACCGTGTTCCGGATGT-3‟ 
H3 Fw 5‟-GAAGAAACCTCATCGTTACAGGCCTGGT- 3‟ 
Rev 5‟-CTGCAAAGCACCAATAGCTGCACTCTGGAA-3‟ 
 
32
P-orthophosphate in vivo labeling and RNA analysis. Cells were incubated with 
phosphate-free medium supplemented with 10% dialyzed FBS (labeling medium) for 
1 h before labeling with 32P-orthophosphate (15 mCi/ml) in labeling medium for 1 h 
(pulse). Medium was then replaced with complete medium (chase). Doxycycline was 
maintained where necessary, for the entire time of the experiment. Total RNA was 
extracted using TRIZOL reagent (Invitrogen) and 1mg of purified RNA was separated 
on 1% agarose–formaldehyde gel. After electrophoresis, 28S and 18S rRNA were 
controlled under UV light and gels were dried.  
 
[
35
S]protein labeling and immune precipitation. For metabolic labeling, HCT116 
cells were preincubated in DMEM without methionine and cysteine with 5% dialyzed 
FCS for 30 minutes. Preincubated cells were treated with proteosome inhibitor, 50 
μM MG132, and labeled with 100 μCi/ml of [35S]methionine and cysteine 
(NEG772014MC Perkin Elmer) for 1 hour. Immune precipitation was performed 
using RIPA buffer, with protease inhibitors. Samples were cleared by centrifugation 
for 30 min at 13,000g at 4 °C and incubated for 1 h at 4 °C with anti-p53 antibody 
(sc-126, Santa Cruz) and anti-HSP90 antibody (sc-13119, Santa Cruz). After 1 h 
incubation with protein G-Sepharose (GE Healthcare), immunoprecipitates were 
washed three times in Co-IP buffer, resuspended in sample buffer, and analyzed by by 
autoradiography. 
 
Co-immune precipitation. Co-IP experiments with Mdm2 or overexpressed proteins 
were performed using Co-IP buffer (NaCl 120mM, Tris-HCl pH8 20mM, EDTA 
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1mM, NP40 0,5%) with protease inhibitors. Samples were cleared by centrifugation 
for 30 min at 13,000g at 4 °C and incubated for 16 h at 4 °C with anti-Mdm2 antibody 
(SMP14; Santa Cruz), anti-HA (Y-11 sc-805, Sigma). After 1 h incubation with 
protein G-Sepharose (GE Healthcare), immunoprecipitates were washed three times 
in Co-IP buffer, resuspended in sample buffer, and analyzed by immunoblotting.  
 
Polysomal fraction and RNA extraction.  Cells were washed once with phosphate 
buffer saline (PBS + cycloheximide 10 μg/ml) and treated directly on the plate with 
300 μl lysis buffer (10 mM NaCl, 10 mM MgCl2, 10 mM Tris–HCl, pH 7.5, 1% 
Triton X-100, 1% sodium deoxycholate, 0.2 U μl-1 RNase inhibitor, cycloheximide 
10 μg/ml and 1 mM dithiothreitol) and transferred to an Eppendorf tube. After a few 
minute incubation on ice with occasional vortexing, the extracts were centrifuged for 
5 min at 12,000 g at 4 °C. The supernatant was stored at −80 °C or loaded directly 
onto a 15–50% linear sucrose gradient containing 30 mM Tris–HCl, pH 7.5, 100 mM 
NaCl, 10 mM MgCl2, and centrifuged in an Sorvall rotor for 100 min at 180,000 g. 
Fractions (polysomal and subpolysomal) were collected monitoring the absorbance at 
254 nm and treated directly with proteinase K. After phenol–chloroform extraction 
and isopropanol precipitation, polysomal RNA was resuspended in 30 μl of water. 
RNA quality was assessed by agarose gel electrophoresis and by the Agilent 2100 
Bioanalyzer platform (Tebaldi et al., 2012). 
 
Migration assay. For analysis of cell migration, transfected cells (0,75-1x10
5
) were 
plated on 24 well PET inserts (8.0 μm pore size, Falcon). After 16 h cells on the upper 
part of the membrane were removed with a cotton swab and cells that had passed 
through the filter were fixed in 4% PFA, stained with 0.05% crystal violet and 
counted. 
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